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ABSTRACT 
South Africa is one of six countries worldwide that has the highest national burden of 
tuberculosis (TB) and the largest number of HIV-infected people in the world. HIV 
infection, Mycobacterium tuberculosis (M.tb) infection and TB disease is most 
common during a woman’s reproductive age, particularly in South African women. 
HIV co-infection increases the risk of TB disease either by facilitating reactivation of a 
latent TB infection or by favouring the progression of a recently acquired TB infection 
towards active disease in HIV-infected patients. Globally, HIV-TB co-infected adults 
are 19 times more likely to develop TB disease than HIV-uninfected adults, in the 
absence of preventive therapy. In South Africa 61% of TB cases are reported to be 
HIV-infected. HIV-infected pregnant women with latent TB infection are more likely to 
progress to active TB disease and women in the early postpartum period are twice as 
likely to develop TB as non-pregnant women, usually at 3 months post-delivery. More 
pregnant women die from TB disease than from any other pregnancy or childbirth 
related causes, particularly in South Africa. This risk is greater in HIV-infected, 
pregnant women, who account for 29.7% of pregnant women attending public 
antenatal clinic services in South Africa. Infants of pregnant women with TB have 
increased risks of mortality and morbidity compared to infants of women without TB, 
and these risks are even higher in pregnant women co-infected with HIV and TB. 
 
The risk of M.tb exposure, infection and TB disease in HIV-exposed, uninfected 
infants is high. An analysis is presented on the relationships between socio-
demographic and clinical risk factors and M.tb infection and TB disease in HIV-
infected mothers and HIV-exposed infants examined in the setting of an infant TB 
vaccine clinical trial. Prevalence of maternal M.tb infection and the incidence rate of 
maternal TB disease and infant M.tb infection and TB disease in this cohort is also 
investigated. 
 
The protocol (Part A) outlines the study design and the methodology of the research 
for this sub-analysis. The literature review (Part B) provides an overview of recent 
and current literature on the prevalence and incidence rate of M.tb infection and TB 
disease in HIV-infected pregnant and post-partum women and their HIV-exposed 
infants in resource-limited settings, particularly in sub-Saharan Africa and specifically 
in South Africa. Literature on the risk factors associated with the exposure and 
progression to M.tb infection and TB disease in these susceptible populations is 
described. The results of the sub- analysis are presented as a manuscript (Part C). 
The main findings are the incidence rate of maternal TB was 1.36/100 person-years 
and incidence rate of infant M.tb infection and TB was 2.47 and 3.62/100 person-
years respectively. Maternal CD4 count >350 cells/mm3 was strongly associated with 
QFT positivity that may have affected the estimate of maternal M.tb infection. Infant 
M.tb infection was driven by new household TB contact(s) as was infant TB disease 
in addition to higher QFT values (IU/ml) and maternal smoking. 
 
Determining which pregnant or postpartum HIV-infected women and their infants are 
at the highest risk of becoming M.tb infected and developing TB disease, by 
improving active TB screening of mother-infant pairs, could be an important public 
health means to reducing the burden of disease and death caused by TB, particularly 
in HIV endemic areas of South Africa where Prevention of Mother to Child 
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Protocol Part A 





1. PROTOCOL SUMMARY 
South Africa is one of six countries worldwide that has the highest national burden of 
tuberculosis (TB) and the largest number of people in the world [1]. More women of 
childbearing age die from TB than from any other pregnancy or childbirth related 
causes in developing countries. This risk is greater in HIV-infected, pregnant women 
[2,3], who account for 29.7% of pregnant women attending public antenatal clinic 
services in South Africa [4]. Infants of pregnant women with TB have increased risks 
of mortality and morbidity compared to infants of women without TB, and these risks 
are even higher in pregnant women co-infected with HIV and TB [5]. 
 
The risk of M.tb exposure, infection and TB disease in HIV-exposed, uninfected 
infants is high [6]. A better understanding of the risk factors associated with M.tb 
infection and TB disease in pregnant or postpartum HIV-infected women and their 
HIV-exposed infants will aid efforts to reduce the burden of disease and death caused 
by TB in these populations, particularly in HIV endemic areas of South Africa where 
Prevention of Mother to Child Transmission (PMTCT) coverage is greater than 95%. 
Improving active maternal, infant and household TB screening and providing TB 
preventive chemotherapy and testing new effective TB vaccine candidates in HIV-
exposed infants in the first year of life is imperative to reduce the burden of TB in this 
population. 
 
No participants will be recruited for this dissertation. The dataset for this sub-analysis 
was generated during an ethics approved, double blind, randomized, placebo- 
controlled, Phase II clinical trial entitled “Phase II Randomised Controlled Trial to 
Evaluate Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille 
Calmette-Guerin (BCG) Vaccination in Infants of HIV-infected Mothers” (protocol 
number G1100570/1). The specific aims of the clinical trial were to evaluate the 
safety and immunogenicity of MVA85A, given at birth, and BCG given at 8 weeks of 
age to HIV-exposed, uninfected infants. All participants were followed for 365 days 
for safety and immunogenicity endpoints. 
 
Statistical analysis of the clinical trial data showed that administering MVA85A to HIV-
exposed infants within 96 hours of birth as a prime vaccine was safe and induced an 
early modest antigen-specific immune response [7]. 
 
The sub-analysis is summarised in the table below. 
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Title The Burden Of Perinatal Tuberculosis In HIV-infected Mothers And Their Infants 
Study 
design 
Sub analysis of data generated during a double blinded, randomised, controlled 
trial. HIV-exposed infants were randomised 1:1 to receive single dose, intradermal 
MVA85A vaccine or Candin® control by intradermal injection within 96 hours of 





Infants (n=248) born to HIV-infected mothers receiving antiretroviral therapy (ART) 
or PMTCT in TB and HIV endemic areas of South Africa (Worcester (South African 
Tuberculosis Vaccine Initiative (SATVI), University of Cape Town (UCT)) and 
Khayelitsha (Desmond Tutu TB Centre (DTTC), Stellenbosch University (SUN)). 
Study 
Objectives 
• To determine the prevalence of and risk factors for M.tb infection in HIV- 
infected, pregnant women 
• To determine the incidence rate of and risk factors for M.tb infection in 
infants of HIV-infected mothers 
• To determine the incidence rate of and risk factors for TB disease in 
infants of HIV-infected mothers 
• To estimate the postpartum incidence rate of and risk factors for TB 




• The QuantiFERON TB assay cannot accurately differentiate between M.tb 
infection and active TB disease or distinguish M.tb reactivation from 
reinfection with the organism. However, since there is no gold standard for 
latent M.tb infection, the QuantiFERON TB assay is an acceptable but 
imperfect test that detects a host cellular immune response to M.tb antigens 
in vitro and is therefore an indirect marker of TB exposure [8]. M.tb infection 
in HIV-infected mothers is defined in this sub-analysis as a positive 
QuantiFERON TB assay result 
 
• M.tb infection in HIV-exposed infants in the clinical trial was assessed by 
QuantiFERON TB assay and not by the Tuberculin Skin Test since prior BCG 
vaccination and exposure to environmental mycobacteria can cause false 
positive results in the Tuberculin Skin Test but not in the QuantiFERON TB 
assay. Incident M.tb infection is defined in this sub-analysis as a positive 
QuantiFERON TB assay result 
 
• Incident TB Disease in HIV-infected mothers is defined as mothers who 
received TB drug treatment. Incident TB disease is defined in HIV-exposed 
infants based on the clinician’s decision to treat for TB, including 
microbiological, radiological and clinical criteria for diagnosis. This definition 
included confirmed, unconfirmed and unlikely TB [9] 
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2. INTRODUCTION 
 
2.1. Burden of disease 
 
Tuberculosis (TB) remains one of the world’s biggest public health threats and 
accounted for 10.4 million new active TB cases in 2015, of which 1.2 million (11%) 
were among people living with HIV, and 1.4 million deaths worldwide [1]. 
 
The national TB and HIV burden in South Africa ranks as one of the highest in the 
world. TB incidence in infants and children is very high: the estimated annual 
incidence of TB in HIV-uninfected children aged 0-4 in Cape Town, South Africa, in 
2009 was 511 cases per 100 000 population [10] and was highest in children aged 
12-23 months [11]. HIV-infected infants were at a 24.1 fold higher risk of pulmonary 
TB and a 17.1 fold higher risk of disseminated TB, compared with HIV-uninfected 
infants [12]. TB is the leading cause of death in South Africa, accounting for 7.2% of 
all deaths [13]. 
 
The HIV status of pregnant women is of critical importance to their health and that of 
their unborn children. HIV infection was associated with an estimated 70% of 
maternal deaths in South Africa [14] and almost 50% of all deaths of children younger 
than 5 years [15]. The majority of infants and children who are HIV-infected were 
infected through mother-to-child transmission (MTCT). The HIV prevalence in 
pregnant women who attended public antenatal clinic services in South Africa was 
29.7% in 2013, which has remained relatively stable since 2004 [4]. The South 
African antiretroviral intervention programme to prevent MTCT (PMTCT) has proven 
to be hugely successful with 95% coverage of HIV-infected pregnant women 
attending public antenatal clinic services [16] and a significant reduction in the MTCT 
rate (at 6 weeks post-partum) from 8% in 2008 to 1.5% in 2015 [16,17]. However, 
despite this decrease, there were still a significant number of new HIV infections in 
children in South Africa [18]. 
 
2.2. Burden of TB in pregnant women and their infants 
 
As with HIV infection, TB is most common during a women’s reproductive age of 15- 
29 years [2] and is a major cause of maternal morbidity and mortality, especially in 
HIV-infected women [3]. HIV-infected pregnant women with latent TB infection (LTBI) 
are more likely to progress to active disease [3] than HIV-uninfected pregnant 
women. Pregnant women with TB/HIV co-infection have poorer outcomes than those 
who are only TB or HIV-infected [19]. TB and HIV infection account for more maternal 
deaths during pregnancy and the postpartum period in Sub-Saharan Africa than 
obstetric causes [2], accounting for 26.3% of maternal deaths in South Africa 
between 2011 and 2013 [20]. Postpartum women are twice as likely to develop TB as 
non-pregnant women [21] with median onset 3 months post-delivery [22]. 
 
Infants of pregnant women with TB have increased risks of adverse outcomes 
compared to infants of women without TB, including perinatal mortality, low birth 
weight and intrauterine growth restrictions [23] and these outcomes are higher in 
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infants born to pregnant women co-infected with HIV and TB than in women infected 
with TB or HIV only [5]. 
 
2.3. Risk factors associated with M.tb infection and TB Disease in pregnant 
and postpartum women and their infants 
 
In endemic areas, most TB transmission to adults is outside the household, whereas 
transmission in young children is from household contact with an infectious TB case 
[25–27]. The risk of M.tb infection and TB disease in children, including those 
younger than 2 years of age, is greater if the household exposure is to a sputum 
smear positive source case, due to greater bacillary loads of these contacts, than to 
sputum smear-negative cases [28]. Furthermore, mothers who are TB and HIV co- 
infected have a 30% higher rate of infecting their children than those with TB alone 
[29]. 
 
The risk of progression from M.tb infection to TB disease is determined by 
microbiological, immunological factors and age [24,28]. Adult TB disease results from 
either recent infection or reactivation of latent or previously acquired infection. 
Pregnancy or the postpartum period affects the course of TB due to the partial 
suppression of the Th1 proinflammatory immune response that can mask symptoms 
of TB and increase the susceptibility to new infection and reactivation. 
 
The risk of TB disease, either reactivation of a latent infection or recent infection, is 
greater in HIV-infected patients [30]. Globally, HIV-infected adults infected with TB 
are 19 times more likely to develop TB than HIV-uninfected adults, in the absence of 
preventive therapy [31]. In South Africa 61% of TB cases are reported to be HIV- 
infected [32]. 
 
In contrast to TB disease progression in adults, childhood TB disease results from 
recent infection. From studies prior to the chemotherapy era, it was shown that HIV- 
infected infants have a 50% lifetime risk of progression to disease following infection 
[28]. Progression to TB disease can occur in children at any age but is most common 
in those younger than 5 years of age and adolescents [23]. Progression to TB is 
usually within 12 months of M.tb infection and 50% of infants will develop TB disease 
during the first year of life if their mothers have active TB disease, in the absence of 
Isoniazid Preventive Therapy (IPT) or if BCG unvaccinated. Young children (under 2 
years of age), HIV-infected children and severely malnourished children infected with 
TB have a more frequent and greater risk of progressing to active TB as well as 
developing serious forms of TB like disseminated TB and TB meningitis [23]. 
 
Besides contact with a source case and HIV infection other risk factors for exposure 
the following to and infection with M.tb and TB disease in infants and children include: 
[33–38] 
- Poverty 
- Composition of the household, as the risk of TB contact increases with more 
adults living in the same house 
- The number of living and sleeping areas in the house 
- Do infants and children sleep with adults or other children 
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- Presence of cigarette smokers in the house 
- Indoor pollution from biofuels used for heating or cooking that may interfere 
with mucosal integrity and mucosal immunity in children 
- Poor ventilation and dark spaces where M.tb-containing droplets stay 
airborne for longer and survive longer than those exposed to sunlight) 
- Alcohol abuse: adults attending informal bars are at increased risk of coming 
into contact with other TB sources 
- Helminth (worm) infestation in infants 




- Diabetes, cancer or silicosis and other immuno-suppressive treatment 
- BCG unvaccinated 
- Migration 
 
2.4. Risk of M.tb infection and TB disease in HIV-exposed, uninfected 
infants 
HIV-exposed, uninfected infants are at an increased risk of exposure to M.tb and are 
at a high risk of developing active TB disease following infection [23], whether they 
are HIV-infected or not [39]. In addition to the risk factors described above, 
specifically household contact [6] and adverse environmental and socio-economic 
conditions, other risk factors include duration of breastfeeding and quality of breast 
milk, severity of maternal HIV disease, immune dysfunction [40] and delay in BCG 
vaccination [7,41] 
 
A better understanding of the risk factors associated with M.tb infection and TB 
disease in HIV-infected mothers and their HIV-exposed infants could allow for 
informed public health planning and targeted use of available healthcare resources in 
an effort to prevent M.tb transmission, M.tb infection and TB disease. Improving 
active maternal, infant and household TB screening and providing TB preventive 
chemotherapy and testing new effective TB vaccine candidates in HIV-exposed 
infants in the first year of life is imperative to reduce the burden of TB in this 
population. 
 
2.5. Context of the dissertation 
The dataset used for this dissertation was generated during a double blind, 
randomized, placebo-controlled, Phase II clinical trial entitled “Phase II Randomised 
Controlled Trial to Evaluate Safety and Immunogenicity of MVA85A and Selective, 
Delayed Bacille Calmette-Guerin (BCG) Vaccination in Infants of HIV-infected 
Mothers” (protocol number G1100570/1). The rationale for this study was that infants 
of HIV-infected mothers are at an increased risk of exposure to M.tb and are at a  
high risk of developing active TB disease [6,39] and are therefore more in need of a 
safe and effective TB vaccine than other infants and children. BCG vaccination 
protects against severe forms of childhood tuberculosis such as miliary TB and TB 
meningitis and therefore BCG vaccination is almost universally given soon after birth 
in tuberculosis endemic regions such as sub-Saharan Africa [42]. However, BCG 
vaccination of HIV-infected infants is associated with severe adverse events 
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including local, regional and disseminated BCG disease and BCG Immune 
Reconstitution Inflammatory Syndrome (IRIS) [41,43,44]. Based on this significant 
risk that outweighs the benefits of BCG vaccination in this population, the WHO 
revised their recommendations in 2007 [45] to no longer give BCG to HIV-infected 
children, even if they are asymptomatic, and to HIV-exposed infants with unknown 
HIV status but who are symptomatic. HIV-exposed infants whose HIV status is 
unknown and who do not have symptoms suggestive of HIV infection should receive 
BCG, as outlined in the guidance document [45,46]. However, most HIV-exposed 
infants are infected peri- or postpartum and are usually not symptomatic at birth. 
Furthermore, at the time of the trial, diagnosis of HIV infection in infants in developing 
countries, particularly South Africa, was between 6-8 weeks of age, which is usually 
after routine BCG has been administered, although in 2015, South Africa 
implemented HIV DNA PCR testing in all HIV-exposed infants at birth [47]. The BCG 
Working Group of the International Union against Tuberculosis and Lung Disease 
(IUATLD), together with the WHO, recognized the challenges for the practical 
implementation of the revised WHO guidelines, specifically the ability of infant 
vaccination programmes, particularly those in high TB endemic countries with limited 
resources, to allow selective, delayed BCG vaccination in HIV-exposed infants from 
birth until 10-14 weeks, following a negative HIV PCR result [41]. Implementation of 
this strategy would reduce disseminated BCG disease in HIV-infected infants yet 
allow HIV-exposed uninfected infants to benefit from BCG vaccination. However, 
delaying BCG vaccination until exclusion of perinatal HIV infection would put infants 
at high risk of acquiring TB in the first weeks of life [7]. Given this risk and that of 
BCG-associated adverse events in HIV-infected infants, a TB vaccination strategy 
that included a priming vaccination with a novel TB vaccine at birth followed by 
routine BCG vaccination of those infants known to be HIV-uninfected was thought to 
be a safe and effective alternative to delayed BCG vaccination alone for HIV- 
exposed infants in settings with a high burden of HIV and TB. 
 
The clinical trial was conducted at two South African TB vaccine trial sites near Cape 
Town. The trial started on 16 November 2012 and follow-up was completed on 12 
May 2015. Immunological data analysis was completed in September 2016. 
 
Information about this trial was disseminated to HIV-infected mothers attending 
routine antenatal PMTCT services by posters, pamphlets. Mothers provided antenatal 
and postnatal written informed consent. A total of 248 HIV-exposed infants were 
randomized in a 1:1 ratio to receive either a single dose of MVA85A vaccine or 
Candin® control by intradermal injection within 96 hours of birth. Assignment to the 
study arms was double blinded Those infants confirmed to be HIV-uninfected by HIV 
PCR at 6 weeks of age were given BCG at 8 weeks of age and were followed for 
safety outcomes as per the study protocol. Infants who were confirmed to be HIV- 
infected by HIV PCR did not receive BCG. All participants were followed-up for 365 
days at scheduled visits for the safety endpoints as well as immunology endpoints. 
 
A requirement for inclusion in the study was participation in the national PMTCT 
programme. Mothers and infants continued to attend PMTCT and Antiretroviral 
Therapy (ART) health services during the trial, from recruitment to the end of follow- 
up. Although the South African ART policies changed in 2013, the guidelines for HIV- 
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exposed infants remained unchanged from those of 2010. Safe infant feeding 
counseling and support is part of the postnatal follow-up of HIV-infected mother- 
infant pairs that is offered at the 6 week EPI visit [48]. Infant feeding choices were 
documented during the trial at the screening visit. 
 
Statistical analysis of the clinical trial data showed that administering MVA85A to HIV-
exposed infants within 96 hours of birth as a prime vaccine was safe and induced an 
early modest antigen-specific immune response [7] 
 
3. RESEARCH QUESTION AND OBJECTIVES 
 
3.1. Research Question 
What is the burden of and risk factors for TB in HIV-infected mothers and HIV- 
exposed infant in the first year of life? 
 
3.2. Hypothesis 
Infants of HIV-infected mothers who are TB infected during pregnancy have a higher 
rate of M.tb infection and disease in the first year of life compared to infants of 
mothers who are not TB infected during pregnancy. 
 
3.3. Objectives 
1. To determine the prevalence of and risk factors for M.tb infection in HIV- 
infected, pregnant women 
2. To determine the incidence rate of and risk factors for M.tb infection in 
infants of HIV-infected mothers 
3. To determine the incidence rate of and risk factors for TB disease in 
infants of HIV-infected mothers 
4. To estimate the postpartum incidence rate of and risk factors for TB 




4.1. Study Design 
No participants were recruited for this sub-analysis (dissertation). The dataset for this 
sub-analysis was generated during a double blind, randomized, placebo-controlled, 
Phase II clinical trial entitled the “Phase II Randomised Controlled Trial to Evaluate 
Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette- 
Guerin (BCG) Vaccination in Infants of HIV-infected Mothers (protocol number 
G1100570/1)” as described in section 3.5 above. 
 
4.2. Study Population and setting 
For the purposes of this sub-analysis, the study population will be 248 infants born to 
HIV-infected mothers receiving ART or PMTCT prophylaxis that met the inclusion 
criteria and had none of the exclusion criteria of Protocol G1100570/1. 
 
The study was conducted at two South African TB vaccine trial sites: 
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4.2.1 South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town (UCT) 
SATVI has a TB clinical trial site in Worcester in the Boland area. The incidence of 
TB in this area in 2007 was 680 per 100 000 overall and 1500 per 100 000 in children 
younger than 2 years of age. At the time of the study, more than 98% of HIV-infected, 
pregnant women who attended local antenatal services participated in the PMTCT 
programme. HIV prevalence in pregnant mothers in the Cape Winelands district in 
2009 was 13.2% and 15% in 2013. Mother to child transmission ranged from 3.2% - 
5.6%. The PMTCT and ART programme for women and children is well established 
in the area. 
 
4.2.2 Desmond Tutu TB Centre (DTTC), Stellenbosch University (SUN) 
SUN has a TB clinical trial site situated in an area of Khayelitsha (Site C), which is 
the largest partially informal township of Cape Town located approximately 35km 
from the city centre. It has an estimated population of 500 000 [49]. The incidence of 
TB in this area in 2009 was 1500 per 100 000 overall and 3290 per 100 000 in 
children less than 18 months of age. Khayelitsha has the highest HIV prevalence in 
the Western Cape Province [49]. The maternal HIV prevalence has increased from 
24.7% in 2002 to 34.3% in 2012, which was higher than the national antenatal rate of 
29.5% [49]. The PMTCT programme has very good coverage in the area with a 
MTCT rate of approximately 2.5% in 2010. HIV care including ART is delivered to 
mother and infants at the clinical trial site. 
 
4.3 Inclusion and Exclusion Criteria (stated verbatim as per Protocol G1100570/1) 
4.3.1 Inclusion Criteria 
• “HIV-infected mother receiving either ART, or started on PMTCT prophylaxis” 
• “Maternal antenatal and post-natal written consent” 
• “Maternal age 18 years or older at the time of consent” 
• “Infant age < 96 hours” 
• “Infant birth and residence in the study area” 
• “Mother contactable and able to attend follow-up visits” 
 
4.3.2 Exclusion Criteria 
• “Neonatal Apgar score <7 at 5 minutes” 
• “Infant birth weight 2,000g or > 4,500g” 
• “Estimated infant gestational age < 32” 
• “Neonatal respiratory distress” 
• “History or evidence of infant congenital abnormality, or immunosuppressive 
condition, other than HIV infection” 
• “Any maternal or infant condition or systemic illness that in the opinion of the 
investigator is likely to affect safety and immunogenicity of study vaccine” 
• “Infant BCG vaccination prior to enrolment” 
• “Residence in a household, or frequent close contact, with an adult diagnosed 
with active TB who has not yet completed TB treatment” 
• “Mother with active TB who has not yet completed TB treatment” 
• “Unknown or negative maternal HIV status” 
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• “Intention to leave the study area and/or unable to attend follow-up visits” 
 
4.4 Measures and procedures 
Clinical trial staff collected and recorded data at scheduled visits on “Days 7, 28, 42, 
56, 63, 84, 112 and 365” as outlined in protocol number G1100570/1. Maternal and 
infant socio-demographic, clinical, maternal-HIV data and active TB surveillance data 
were recorded at these visits and will be included in sub-analysis (Tables 1). 
 
4.4.1 QuantiFERON (QFT) assay 
QuantiFERON-TB Gold (QFT, Qiagen) was performed on all mothers at enrolment 
and on infants who successfully completed one year of follow-up, if not previously 
investigated as described in section 5.4.4. The QFT assay is an indirect test for latent 
tuberculosis infection. The assay was performed in the SANAS accredited 
laboratories at SATVI according to the manufacturer’s instructions (Qiagen QFT 
package insert) [50]. This whole blood interferon-gamma (IFN-γ) release assay 
(IGRA) measures cell mediated immune responses to the M.tb-specific ESAT-6, 
CFP-10 and TB7.7 (p4) peptides that are associated with M.tb infection. Heparinized 
whole blood is added to the following tubes: 
 
• TB antigen tube: Contains M.tb-specific proteins 
• Negative control tube: No TB antigens or other additives (Nil tube) to 
determine non-specific IFN-γ production. 
• Positive control tube: Contains a non-TB antigen (Mitogen) for IFN-γ 
production that contains a non-TB antigen. 
 
Production of IFN-γ from blood stimulated by the M.tb antigens is detected by ELISA 
and measured in IU/ml. Results are interpreted as: 
 
• Negative: IFN-γ value minus that of the Nil tube = < 0.35 IU/ml. 
• Indeterminate: A low IFN-γ response to Mitogen and to the TB antigens. 
• Positive result: IFN-γ value in the TB Antigen tube > 0.35 IU/ml 
 
 
The QFT assay results were recorded on the database as IFN-γ values in IU/ml 
(Quantitative result) and qualitatively as positive, (TB antigen minus nil IFN-γ value > 
0.35 IU/ml as per the manufacturer’s instructions), negative (IFN-γ value < 0.35  
IU/ml) or Indeterminate. In this sub-analysis, QFT Indeterminate results for both 
mothers and their infants were included as QFT negative results. 
 
4.4.2 Study Outcomes (endpoints) 
The outcomes (or endpoints) of the dissertation are defined as follows: 
 
4.4.3 Maternal and Infants M.tb infection outcomes 
QFT cannot accurately differentiate between M.tb infection and active disease or 
distinguish reactivation from reinfection [8]. However, since there is no gold standard 
for LTBI, QFT is an acceptable but imperfect test that detects a host cellular immune 
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response to M.tb antigens in vitro and is therefore an indirect marker of M.tb 
exposure [8]. 
 
Although QFT has not been validated as a diagnostic test for M.tb infection in infants 
and children younger than 2 years of age, a study done by the SATVI group showed 
that both TST and QFT had excellent concordance in children younger than 3 years 
of age in a high TB burden setting and equivalent performance of both tests in the 
diagnosis of TB disease [11]. Since TST is confounded by prior BCG vaccination and 
exposure to most environmental mycobacteria, whereas the QFT assay is not, QFT 
was used as an efficacy endpoint definition of M.tb infection in BCG-vaccinated 
infants at the SATVI site under a tuberculosis vaccine trial setting [51]. 
 
In this sub-analysis, M.tb infection in HIV-infected mothers and HIV-exposed infants 
is defined as a positive QFT result. 
 
4.4.4 Maternal and Infant TB Disease outcomes 
Participants with suspected TB disease were investigated at local hospitals. Maternal 
incident TB disease is defined as mothers who receive TB drug treatment. Incident 
TB disease is defined in infants based on the clinician’s decision to treat for TB, 
including microbiological (notably TST or QFT), radiological or clinical criteria for 
diagnosis. This definition includes confirmed, unconfirmed and unlikely TB [9] 
 
5. DATA MANAGEMENT AND STATISTICAL ANALYSIS 
 
5.1. Data Management 
Management, validation and verification of the clinical trial data was per protocol and 
the Data Management plan. The clinical trial Data Manager will extract the dataset for 
this sub-analysis from the clinical trial database as a Microsoft Excel spreadsheet. 
Any queries relating to this dataset will be directed to the Data Manager, who will 
provide additional data if required. 
 
5.2. Statistical Analysis 
The dataset used for this sub-analysis will be analysed using STATA version 12.0 
(DataCorp, USA). Variables to be analysed for independent associations in HIV- 
infected mothers and their HIV-exposed Infants are shown in Tables 1 and 2 
respectively. Variables were selected for analysis based on their possible 
associations with maternal and infant M.tb infection and TB disease and for their 
clinical or biological significance, particularly in HIV-infected, postpartum mothers and 
their HIV-exposed infants, as reported in several studies in the literature and 
described in sections 3.3 and 3.4 above. Categorical and numerical variables will be 
coded in the sub-analysis as shown in Tables 1. 
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Table 1. Variables to be analysed in HIV-infected mothers and HIV-exposed infants 
Variable name Variable Type Variable coding Variable explanation 
Maternal Age Numerical (Continuous) Years Age at time of enrolment 
Number of other adults 
in household 
Numerical (Discrete) Count Number of other adults living 
in the household 
Number of other infants 
in the household 
Numerical (Discrete) Count Number of infants besides 
the enrolled infant living in 
the house 
Number of sleeping 
rooms 
Numerical (Discrete) Count Number of rooms in the 
house used for sleeping 
Highest Educational 
level 
Categorial (Nominal) 1 = Primary school 
2 = Junior High school 
3 = Senior High School 
Level of education from 
Grade 1- 7 is classified as 
primary school level; Grades 
8-10 as junior high school 
and Grades 11-12 as senior 
high school 
Employment status Categorical (Binary) 1 = employed 
0 = unemployed 
Whether mother was 
employed or unemployed 
Employment type Categorical (Nominal) 1 = Formal sector 
2 = Informal sector 
3 = Farm 
Whether mother was 
employed in the formal, 
informal sector or worked on 
a farm 
ART treatment Categorical (Binary) 1 = ART 
0 = PMTCT 
Type of antiretroviral therapy: 
prevention of mother to child 
transmission (PMTCT) 




Categorical (Binary) 1= Yes; 0 = No Household or close contact 
with TB at enrolment 
New TB household 
contact 
Categorical (Binary) 1= Yes; 0 = No Household or close contact 
with TB since enrolment 
Maternal CD4 count Numerical (Continuous) Cells/mm3 Recent maternal absolute 
CD4 count 
Maternal Viral load Numerical (Continuous) Copies/ml Measure of amount of HIV 
genetic material (RNA) per 
milliliter of blood 
Maternal Smoking Categorical (Binary) 1 = Yes; 0 = No Smoking status of mother 
Maternal and infant 
Qualitative QFT 
Categorical (Binary) 1 = Positive 
0 = Negative 
QFT positive or negative 
(including Indeterminate 
results) 
Maternal and infant 
QFT IFN-γ 
Numerical (Continuous) IU/ml Quantitative value of IFN-γ in 
the TB antigen minus nil tube 
Maternal IPT Categorical (Binary) 1 = Yes; 0 = No Whether mother was 
currently on Isoniazid 
treatment at baseline 
Maternal TB Disease Categorical (Binary) 1 = Yes; 0 = No Whether mother was being 
treated for TB 
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Infant Gestational age Numerical (Continuous) weeks Estimated number of weeks 
that the infant was in the 
uterus 
Birth weight Numerical (Continuous) grams Weight of infant at birth 
Length Numerical (Continuous) cm Length of the infant at birth 
Head circumference Numerical (Continuous) cm Head circumference 
measurement at birth 
Gender Categorical (Binary) 1= Male 
0 = Female 
Gender of infant 
Feeding choice Categorical (Binary) 1 = Breast Milk 
0 = Formula 
Whether infant was breast 
fed, formula fed or a mixture 
of breast and formula feeding 
Infant HIV Status Categorical (Binary) 1= HIV-infected 
0 = HIV-uninfected 
HIV status of the infant 
Infant TB Disease Categorical (Binary) 1 = Yes; 0 = No Based on clinician’s decision 
to treat for TB 
 
Objective1: The prevalence of M.tb infection in the mothers will be estimated as the 
number of mothers with a positive QFT at the time of enrollment divided by the total 
number of mothers whose infants were enrolled into the study. 
 
Objective 2: The incidence rate of M.tb infection in infants will be calculated as 
person years of follow-up using the number of infants with a positive QFT at Day 365 
divided by the total number of infants who successfully completed one year of follow-
up. 
 
Objective 3: The incidence rate of TB disease in infants will be calculated as person 
years of follow-up using the total number of infants who successfully completed 
follow-up divided by the number of infants who were treated for TB during follow-up 
as the numerator. 
 
Objective 4: The incidence rate of TB disease in mothers will be calculated as person 
years of follow-up of infants using the total number of infants who successfully 
completed follow-up divided by the number of mothers who were treated for TB 
during follow-up as the numerator. 
 
Descriptive statistics of maternal and infant baseline demographic and clinical data 
for continuous data will include number of observations, mean and standard deviation 
for normally distributed data or median and interquartile range (IQR) for skewed data 
and number of observations, their frequencies and percentages for categorical 
variables. 
 
Univariate associations of socio-demographic and clinical risk factors with maternal 
and infant QFT positivity and TB disease will be assessed by Chi-squared or Fisher’s 
Exact tests and odds ratios (OR) with 95% confidence intervals (95% CI). Those risk 
factors with a P value <0.05 or that are deemed to be of biological precedence with or 
without a P value <0.25 will be considered for multivariable logistic regression 
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models to explore independent associations between these risk factors and QFT 
positivity or TB disease in mothers and infants. 
 
The QFT manufacturer’s recommended threshold for a positive test result of > 0.35 
IU/ml is under debate. It is unclear whether higher IFN-γ values represent more 
recent M.tb infection, greater aerosolized inoculum, or sustained infection [52,53].  
For these reasons, it is of interest to investigate the association of risk factors with 
M.tb infection (measured by maternal and infant continuous QFT IFN-γ (IU/ml) 
values), particularly those >0.35 IU/ml, in linear regression models. Non-normally 
distributed dependent variables will be log transformed and coefficients interpreted as 
percentages. Regression diagnostics will be run to check whether the assumptions of 
linearity, normality of residuals (errors), homogeneity of variance and independence 
underlying the regression model are met justified and to identify outliers and 
influential points. 
 
Table 2 is an example of how results will be presented for M.tb infection (QFT 
positivity) in HIV-infected mothers; in HIV-exposed infants; and for TB Disease in 
HIV-infected mothers; and in HIV-exposed infants. Results will be presented 
graphically where appropriate. 
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Table 2. Dummy table of univariate and multivariable models of socio-demographic 












Univariate analysis Multivariable 
analysis 
OR (95% CI) P 
value 
OR (95% CI) P 
value 
Age (Median; IQR)       
Number of other 
(Median, IQR) 
adults in household       
Number of other 
(Median, IQR) 
children in household       
Number of Sleeping rooms (Median, IQR)       




      
Employment status: (n,%) 
Employed (=1) 
Unemployed 
      




      
ART treatment: (n,%) 
PMTCT 
ART (=1) 
      
Household TB contact (baseline; n,%)       
Previous TB Treatment (n,%)       
CD4 count (cells/mm3) (median, IQR)       
CD4 count category (n, %) 
< 350 
> 350 (=1) 
      
Smokes (n, %)       
IPT treatment (n, %)       
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6. ETHICS AND COMMUNICATION 
No participants will be recruited for this sub-analysis as the research will be 
conducted using an existing dataset that was generated during the clinical trial. The 
protocol (number G1100570/1) received approval from the University of Cape Town, 
Faculty of Health Sciences Human Research Ethics Committee (HREC) on 6 March 
2012 (013/2012), the Stellenbosch University HREC on 23 May 2012, the Oxford 
Tropical Research Ethics Committee on 4 April 2012 and the South African 
Medicines Control Council (MCC) on 26 March 2012 (Appendix A: Copies of HREC 
and MCC approval letters). Ethics approval from UCT’s Faculty of Health Sciences 
HREC will be sort for the use of the data set in this sub-analysis. 
The ethical principles of beneficence, non-maleficence, autonomy and justice of the 
clinical trial were described in the study protocol. The clinical trial was conducted in 
accordance with the Declaration of Helsinki (version 2008), Good Clinical Practice 
(ICH-GCP), South African Good Clinical Practice Guidelines and the regulations of 
the MCC. All study staff, including this candidate, was trained on the study protocol 
and were certified in Good Clinical Practice (ICH-GCP). 
The potential benefits, risks and measures to minimize risk in this dissertation are 
addressed as follows: 
 
6.1. Beneficence 
There will be no direct benefit for the participant’s whose data will be analysed in this 
dissertation. However, determining the risk factors associated with M.tb infection, TB 
transmission and TB disease in pregnant or postpartum HIV-infected women and 
their infants will potentially benefit this population to reduce the burden of disease 
and death caused by TB. This could be achieved by improving TB control strategies, 
such as maternal, infant and household screening and providing necessary TB 




There is no anticipated harm or discomfort to the participants as data that was 
previously collected during the approved clinical trial will be analysed in this 
dissertation. Maintaining participant confidentiality is of great importance. Access to 
the clinical trial database is password restricted to the data management team and 
certain study staff designated by the Principal Investigator. The clinical trial data 
manager will extract the data set for this dissertation from the clinical trial’s database 
as a Microsoft Excel document. Any additional information that may be required from 
the database will be done so through the data manager. The participant identification 
numbers that will be included in the data set are unique and coded. The candidate 
will not have access to any information that could identify the participant. There will 
therefore not be any breach of participant confidentiality. Participant data will be 
reported in such a way that no participant might be recognized from any publication. 
 
6.3. Respect for Autonomy 
Information about the clinical trial was disseminated to mothers attending routine 
antenatal PMTCT services either via posters and pamphlets or group information 
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sessions. Mothers of potential participants received information about the study from 
a study staff member before signing a written informed consent document. After the 
birth of their infants, mothers who still wanted their infants to participate in the study 
signed the informed consent document a second time to reaffirm their decision. 
Those mothers who no longer wanted their infants to participate in the study were 
given the opportunity to withdraw consent, without prejudice, by not re-signing the 
informed consent form. Participation was voluntary. Since no participants will be 
recruited for this dissertation there is no need to re-affirm participation by written 
informed consent will not be re-affirmed. Participant data used in this dissertation will 
remain de-identified to maintain participant confidentiality. 
 
6.4. Justice 
TB-HIV co-infection is a major cause of maternal mortality and morbidity during 
pregnancy and the postpartum period, which heavily impacts on the mortality and 
morbidity of their infants. Although it has been shown that the rate of TB exposure in 
HIV-exposed, uninfected infants is high [6], currently, there are limited data on the 
risk of M.tb infection and TB disease in HIV-exposed, uninfected infants in the era of 
expanded ART access and effective PMTCT. These vulnerable populations have the 
greatest need for improved TB control strategies and TB interventions. 
 
7. REPORTING AND PUBLICATION 
 
The findings from this dissertation will be reported to the sponsor (UCT) and relevant 
stakeholders. A manuscript will be published in an accredited scientific journal. 
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Structured literature review Part B 
1 Literature review  
1. INTRODUCTION 
 
Tuberculosis (TB) remains one of the world’s biggest public health threats despite a 
worldwide decrease in TB incidence and mortality since 2000 [1]. In 2015, the 
estimated TB incidence worldwide was 10.4 million new active TB cases. TB claimed  
the lives of an estimated 1.4 million people worldwide in 2015, with an additional 0.4 
million deaths in people living with HIV. Mortality rates were high in children with TB, 
especially those younger than 5 years of age and those co-infected with HIV. South 
Africa has one of the highest burdens of TB and HIV in the world, with an estimated 
incidence of 454 000 new TB cases per year and one in five of all HIV-infected 
people, living in South Africa [1]. TB is the leading cause of death in South Africa, 
accounting for 7.2% of all deaths [2] with a TB mortality rate in HIV-uninfected people 
of 44/100 000 population in 2015, more than double the global estimate [1,3], and 
133/100 000 population in HIV- infected people [1]. 
 
Mycobacterium tuberculosis (M.tb) infection, TB disease and HIV infection are most 
common in women of reproductive age (15-49 years of age), particularly in South 
African women [1], and are a major cause of maternal morbidity and mortality in 
these women [4]. HIV-infected pregnant women with latent TB infection (LTBI) and 
women in early postpartum are at greater risk of developing TB disease than HIV-
uninfected, non-pregnant women [4,5]. Maternal HIV and TB co-infection has serious 
consequences on infant morbidity and mortality [6]. In particular, the rate of M.tb 
exposure in children born to HIV-infected mothers is high, and they are at a high risk 
of developing active TB disease following infection, including those who remain HIV-
uninfected, in high TB burden settings [7– 9]. 
 
Here, the existing literature was examined in order to understand the relationship 
between socio-demographic and clinical risk factors and M.tb infection and TB 
disease particularly in HIV-infected mothers and their HIV-exposed infants. 
 
2. OBJECTIVES OF THE LITERATURE REVIEW 
 
The focus of this study is to determine the burden of and risk factors for TB in HIV- 
infected mothers and HIV-exposed infants in the first year of life, specifically in a 
population enrolled in a TB vaccine trial in TB and HIV endemic areas of South 
Africa. The literature review aims to illustrate the importance of the study by 
examining the existing literature on the prevalence and incidence of M.tb infection 
and TB disease specifically in the context of HIV, and the risk factors that determine 
the transition from M.tb exposure to M.tb infection and to TB disease in infants and 
adults [10,11] but specifically in HIV-infected pregnant and postpartum women and 
the infants in resource-limited settings, particularly in South Africa. The literature 
review also aims to identify any gaps in the literature. 
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3. LITERATURE SEARCH STRATEGY 
 
Online searches for review and study-specific articles, global and national guidelines 
and government policy documents were conducted between August 2013 and 
February 2018. Majority of the literature reviewed were published between 2009 and 
2017, covering the period of the TB vaccine. Peer-reviewed articles preferably 
published in high impact journals in English and with online access to the full text, 
were selected. Further sources were identified by searching reference lists at the end 
of recently published articles selected in the initial searches. Medical subject 
headings (MeSH) or keywords were used to search the databases of Google and 
PubMed. The search phrases or keywords included, among others: TB burden, TB 
prevalence, TB incidence, TB risk factors, HIV-infected in pregnant women, HIV- 
infected postpartum women, HIV-exposed infants and TB, TB diagnosis, including 
QuantiFERON or gamma interferon release assays, PMTCT and ART. A literature 
review matrix (Table 1) outlines the criteria for inclusion in this review. 
 
3. SUMMARY OF LITERATURE 
3.1 Burden of HIV Infection in perinatal women 
 
Approximately one fifth of South African women of reproductive age are HIV-infected 
[12]. Of major concern is the population of young South African females aged 15 – 24 
years. This age group of females has the highest incidence of HIV compared to any 
other group of females or males, accounting for nearly 37% of annual new HIV 
infections [13]. The HIV status of pregnant women is of critical importance to their 
health and that of their children: between 2005 and 2010, HIV infection was 
associated with an estimated 70% of maternal deaths (WHO definition: during 
pregnancy or between 42 days and 1year post termination thereof [14]) in South 
Africa [15] and almost 50% of all deaths of children younger than 5 years [16], 
although these rates dropped significantly by 2015 [2,17]. HIV prevalence in pregnant 
women who attend public antenatal clinic services in South Africa is approximately 
30% [13], which has remained relatively stable since 2004 [18]. The majority of 
infants and children who are HIV-infected were infected through mother- to-child 
transmission (MTCT). Of increasing significance to the vertical transmission of HIV is 
maternal HIV seroconversion during late pregnancy, after antenatal screening, and 
while breastfeeding [19]. The South African prevention of MTCT (PMTCT) 
programme has proven to be effective: there is greater than 95% antenatal HIV 
testing of HIV-infected pregnant women attending antenatal services, >92% uptake of 
CD4 cell count testing, increased antiretroviral therapy (ART) uptake and increased 
infant prophylaxis uptake [20] and there has been significant progress in reducing the 
early MTCT rates (at 6 weeks postpartum) from 3.5% in 2010 to an estimated 1.2% in 
2016 [20,21]. 
3.2 Burden of TB in perinatal, HIV-infected women 
 
As with HIV infection, M.tb infection and TB disease is most common during a 
women’s reproductive age of 15 to 29 years and is a major cause of maternal 
morbidity and mortality, especially in HIV-infected women [4].  
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Routine screening for M.tb infection and TB disease during pregnancy is not  
standard practice in majority of countries [4,22] and diagnosis is difficult as 
physiological changes associated with pregnancy may mask early TB  symptoms 
[23]. The prevalence of active TB among pregnant women is estimated to be 0.07%- 
0.5% in HIV-uninfected women and 0.7%-11% in HIV-infected women in high burden 
countries [5]. HIV-infected pregnant women with LTBI are more likely to progress to 
active disease [4]. TB disease is a major cause of maternal morbidity and mortality, 
especially in HIV-infected women [2], accounting for 15 to 35% of maternal deaths 
worldwide in 2013 [24] and 26.3% of maternal deaths in South Africa between 2011 
and 2013 [25]. The risk of maternal morbidity in pregnant women with active TB was 
reported to be three times greater than pregnant women who did not have TB [25,26] 
and these outcomes are worse in pregnant women with TB-HIV co-infection than in 
those who are only TB or HIV-infected, with an increased risk of maternal and infant 
mortality of 300% [6]. Pregnancy complications in women with TB include greater 
odds of antenatal admission and miscarriage, postpartum haemorrhage, difficulties in 
labour and pre-eclampsia [26,27]. 
 
The risk factors affecting maternal outcomes include TB-HIV co-infection, site of 
disease (pulmonary or extrapulmonary), timing of TB diagnosis and type, timing of 
initiation and length of TB drug treatment [27,28]. Studies have shown that maternal 
(and perinatal) outcomes in pregnant women with TB are better when treatment is 
initiated in the first trimester as opposed to initiation in the second or third trimester 
[27]. 
 
Postpartum women are twice as likely to develop TB as non-pregnant women [29], 
with reported incidence rates of 5% [30] and 11% [31] with median onset at 3 months 
post-delivery [30]. 
 
3.2.1 Infant mortality and morbidity associated with maternal HIV co-infection 
 
Infants of pregnant women with TB have increased risks of adverse outcomes 
compared to infants of women without TB. These include an increased risk of 
perinatal death [6], preterm birth, low birth-weight [6,28] and “small for gestational 
age” compared to babies born to mothers without TB [27,32]. These perinatal 
outcomes are higher in women co-infected with HIV and TB than in pregnant women 
infected with either TB or HIV [5]. 
3.3 Risk factors of maternal M.tb infection and TB disease 
 
Risk of exposure to TB is associated with the prevalence of active pulmonary TB in a 
given population, is influenced by several risk factors [10,33] and is greater in high 
TB prevalence regions [34]. Transmission of TB is almost exclusively airborne, from a 
source with active pulmonary TB disease. The risk of becoming infected depends on; 
• Infectivity of the TB case (frequency of coughing, density of bacilli in the 
sputum and microbial virulence), 
• Intensity and duration of the exposure to the TB case 
• Susceptibility of that person to infection [10]. 
4 Literature review  
The lifetime risk of developing TB disease in healthy M.tb infected individuals is 5- 
15% and is highest in the first two years of infection. Adult TB disease results from 
either recent infection or reactivation of latent or previously acquired infection. In 
endemic areas, most transmission of TB to adults appears to occur outside the 
household [35–37], possibly at places of social gatherings such as informal bars 
(shebeens), churches, hospitals or clinics and public transport in minibus taxis, or 
prior imprisonment [37]. 
 
HIV co-infection is recognized as the strongest risk factor for TB disease increasing 
the risk either by facilitating reactivation of a latent infection or by favouring the 
progression of a recently acquired infection towards active disease in HIV-infected 
patients [38]. Globally, HIV-infected adults infected with TB are 19 times more likely 
to develop TB than HIV-uninfected adults, in the absence of preventive therapy [39]. 
In South Africa 61% of TB cases are HIV-infected [40]. A recent study showed that 
TB incidence rates were higher in HIV-infected individuals than HIV-uninfected 
individuals living in the same community, despite ART [41]. Middelkoop et al (2015) 
[37], found that 60% of TB cases among HIV-infected patients, including those 
receiving ART in a high HIV and TB burden area with high ART coverage, were from 
recent M.tb infection. Lawn et al (2009) [42] demonstrated that TB incidence was 
higher in those with CD4 counts <200 cells/∝l who were on ART for the first 4months, 
although TB rates remained high at CD4 counts between 200-500 cells/∝l during long-
term ART. 
 
Pregnancy affects the course of TB, as a result of immunological changes that can 
mask symptoms of TB and increase the susceptibility to new infection and 
reactivation and more rapid progression to TB disease [4,22]. Pregnancy is a risk 
factor for development of TB disease in HIV-infected women with LTBI in endemic 
areas [4,43]. Risk factors for TB disease in postpartum HIV-infected women included 
a CD4 count <200 cells/mm3, an HIV viral load of > 50 000 copies/ml and M.tb 
infection [30] as well as subclinical TB during pregnancy, nutritional stress due to 
lactation, lack of sleep, rapid hormonal changes and an altered immune response 
[30]. 
 
Besides contact with a source case, HIV status and pregnancy or postpartum, other 
risk factors include [28,37,44–46]: 
 
- Low socio-economic status, the main confounder for TB exposure, infection 
and disease. 
- Age, particularly maternal 
- Genetic susceptibility (certain host genes may play a role in determining 
susceptibility) 
- Ethnicity 
- Diabetes, cancer, silicosis and other immunosuppressive treatment 
- Previous TB treatment 
- Smoking 
- Alcohol misuse and drug abuse as adults may frequent places such as bars 
that are more likely to have other TB sources, increasing the risk of 
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developing TB due to impaired immunity and are less likely to have 
successful TB treatment 
- Overcrowding 
- Migration from rural areas to urban residences and back. 
 
3.4 Burden of TB in infants 
 
Of the estimated 10.4 million new active cases of tuberculosis globally [1], 1 million 
(10%) were among children (0-14 years). The mortality rate in children with TB, 
especially those younger than 5 years of age, and those who are HIV-infected, is 
very high with an estimated 169 000 (31%) deaths in HIV-uninfected children and 41 
000 deaths in HIV-infected children in 2015 [1]. Mortality is significantly higher in 
children aged 0-4 years than in those aged 5-14 years [47]. 
 
The WHO estimated TB incidence in South African children (0-14 years) was 33 000 
in children in 2015 [1]. There is limited data on the estimates of TB incidence in 
children under the age of 5 and infants aged 1 year and younger in South Africa as 
most estimates report TB in children between the ages of 0 and 14 only. Also, 
diagnosis of paediatric TB is difficult, as childhood TB is usually paucibacillary, 
leading to undiagnosed and hence untreated TB disease. South African studies 
showed a high burden of TB in children younger than 5 years of age in Cape Town 
and surrounding areas, with the highest incidence in those aged 12-23 months [48]. 
The TB incidence in HIV-uninfected children younger than 2 years old in 2002 was 
between 858-866/100 000 person-years [49] and 511/100 000 population in a cohort 
of HIV-uninfected children younger than 5 years of age in 2009 [50]. The estimated 
incidence of TB in a population of infants aged 1 and younger between 2004-2006 
was 1596/100 000 in HIV-infected infants and 66/100 000 in HIV-uninfected infants 
[51]. 
3.5 Burden of TB in HIV-exposed, uninfected infants 
 
Although the number of HIV-infected infants is declining due to expanding PMTCT 
programmes providing ART during pregnancy, delivery and breastfeeding [52], the 
number of HIV-exposed, uninfected infants is increasing. These infants have been 
exposed to HIV in utero and in some cases to multiple antiretroviral drugs at birth or 
throughout the period of breastfeeding [53], for which the effect on their health is 
uncertain. Several studies have shown that these HIV-exposed, uninfected infants 
have increased mortality rates, increased infectious morbidity, immune dysfunction 
and impaired growth compared with HIV-unexposed infants [52,53]. Mortality of HIV-
exposed, uninfected infants in a large study done before maternal ART was widely 
used, was as much as two to four times as high [52,54] as that of HIV-unexposed 
infants. HIV-exposed, uninfected infant mortality was inversely affected by maternal 
CD4 count (the lower the maternal CD4 count, the higher the risk of infant mortality), 
was higher in the first year of life, and was influenced by the time of weaning from 
breast milk [52]. Infant morbidity and mortality was mainly due to lower respiratory 
tract and gastrointestinal infections [52,55]. Infants of HIV-infected mothers are at 
increased risk of exposure to M.tb and high risk of developing active TB disease 
following infection [7], whether they are HIV-infected or not [7–9]. In a South African 
study, the estimated incidence of TB exposure was 10.03% and a rate of disease of 
2% [7]. In another South African study, the incidence of TB in HIV-exposed, 
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uninfected children younger than 2 years of age was reported to be 4.1% and 12.1% 
in HIV-infected infants [8]. Up to 50% of HIV-exposed, uninfected infants will develop 
TB, 30% of whom will have disseminated disease following M.tb exposure and 
infection [56]. 
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3.6 Risk factors of childhood M.tb infection and TB disease 
 
Infants or young children with new M.tb infection represent recent and ongoing 
transmission within the community and therefore act as a sentinel for  TB 
transmission [57,58]. Rates of childhood M.tb infection are associated with 
prevalence of adult TB in the same community [59]. In contrast to TB disease 
progression in adults, childhood TB disease results from recent infection, 
predominantly from exposure to sputum smear positive adult household contacts, as 
child-child transmission is not common [57]. In 2015, globally an estimated 1.2 million 
children under the age of 5 years had a household contact with active TB [1]. Older 
children interact more with adults than younger children and they can therefore either 
be infected at home, within close social networks [57] or within the community. The 
risk of M.tb infection and progression to TB disease in children, including those 
younger than 2 years of age, was greater if household exposure was to a sputum 
smear-positive source case, due to greater bacillary loads of these contacts, than to  
a sputum smear-negative source case, such as HIV-infected adults [11,58]. 
 
The risk of infection increases with more daily interaction and longer duration of 
contact with the source case [11]. Progression to disease is usually within 12-23 
months of infection [49] with an estimated 50% of infants progressing to TB disease 
in the first year of life if their mothers have active TB disease, in the absence of 
Isoniazid Preventive Therapy (IPT) or if Bacillus Calmette-Guérin (BCG)- 
unvaccinated [60]. 
 
Age is an important risk factor in disease progression [11,34]. Infected infants have a 
50% lifetime risk of progression to disease following infection [11], whilst children 
from 1-2 years and 3-5 years of age have a 20-30% and 5% risk, respectively. The 
risk in those 5-10 years old and older than 10 years have a 2% and 5% risk, 
respectively [34]. Chronic malnourished children have an increased risk of TB 
disease, including extrapulmonary disease because of an altered immune response 
[61]. 
 
Vertical transmission of TB (congenital TB) to the foetus in utero or intrapartum is 
considered to be rare in low HIV burden settings and difficult to diagnose, but can 
occur, particularly if the mother is HIV-infected and has disseminated TB, miliary or 
meningeal TB [17,28,62]. Studies conducted in South Africa reported congenital TB 
in 3-16% infants [28,30,46] born to HIV-infected women. Mortality is high at 22-50% 
[56]. 
 
HIV infection is a very significant risk for childhood TB disease. HIV-infected children 
are at increased risk of progressing to active TB as well as developing serious forms 
of TB such as disseminated (miliary) TB and TB meningitis [60] and are more likely to 
have HIV-TB co-infection that increases the child’s risk of M.tb exposure. In a South 
African study, HIV-infected infants were at a 24.1 fold higher risk of pulmonary 
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TB and a 17.1 fold higher risk of disseminated TB compared with HIV-uninfected 
infants [51]. 
 
Other risk factors, besides HIV infection for exposure to and infection with M.tb and 
TB disease in infants and children include (Figure 1): 
3.6.1 Socio-demographic and economic factors 
 
- Composition of the household, as risk of TB contact increases with more 
adults living in one house [34] 
- Physical structure of the house i.e how many rooms there are as living areas 
[63] 
- Sleeping arrangements (infants and children may sleep with adults or with 
other children) [34] 
- Presence of tobacco/cigarette smokers in the house [58,64] as smoke 
exposure is associated with M.tb infection in children with adult TB contact 
[65–67] 
- Indoor pollution from biofuels used for heating or cooking may interfere with 
mucosal integrity and mucosal immunity 
- Poor ventilation in the home, where droplet tubercle bacilli stay airborne for 
longer and survive longer in dark spaces than if exposed to sunlight [34] 
- Alcohol abuse [34] 
3.6.2 Biological/clinical risk factors 
 
- Helminth (worm) infestation [34] 
- Genetic susceptibility and race/ethnicity [10,33] 
- Breastfeeding or Formula Feeding (in low resource settings) present risks for 
M.tb infection (and other infections) from mother, although the risk of M.tb is 
negligible if breast feeding is exclusive and mother has been on anti-TB 
therapy [5,62] 
- Lack of BCG vaccination, which can protect against TB, especially 
disseminated TB and TBM in children [68]. 
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Figure 1: Risk factors for tuberculosis exposure, infection and disease in children. Source: Seddon and 
Shingadia, 2014 [34] 
 
 
3.7 Risk factors of M.tb infection and TB disease in HIV-exposed, uninfecetd infants 
 
Data on M.tb infection and TB disease is limited in HIV-exposed, uninfected infants. 
In addition to the risk factors described in section 3.6, specifically household contact 
[7] and adverse environmental and socio-economic conditions, other risk factors 
include duration of breastfeeding and quality of breast milk, severity of maternal HIV 
disease [53] and vertical transmission of TB [46]. Immune dysfunction has been 
reported in HIV- exposed infants and immune activation could lead to increased 
susceptibility to infection [53]. BCG vaccination is contra-indicated in HIV-infected 
infants due to the risk of local and disseminated BCG disease and BCG immune 
constitutional inflammatory syndrome (BCG-IRIS) [68,69]. However, delaying BCG 
vaccination in HIV-exposed infants until they are confirmed HIV-uninfected puts these 
infants at risk of being infected with M.tb in the first weeks of life in high TB and 
maternal HIV prevalent settings [69,70]. 
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4. NEED FOR FURTHER RESEARCH 
 
Further research into HIV-infected pregnant and postpartum women is necessary 
especially with respect to the epidemiology, immunology and pathogenesis of 
tuberculosis [5]. 
 
More population-based estimates of TB incidence in HIV-uninfected and HIV-, 
infected infants and children younger than 5 years in resource-limited, high HIV and 
TB disease burden settings are needed and there is a need for longitudinal studies 
on M.tb exposure, infection and TB disease, particularly in the increasing population 
of HIV-exposed, uninfected infants. Longitudinal studies are required to investigate 
the immunological and biological mechanisms that result in increased mortality and 
infectious morbidity and impaired growth in HIV-exposed, uninfected infants [54]. An 
important public health question to investigate is whether these outcomes are a result 
of long-term HIV-1 and/or in utero ART exposure or whether these outcomes are a 
result of adverse socio-economic factors associated with being born into an HIV-




HIV-infected pregnant women with LTBI and in early postpartum are at greater risk of 
M.tb infection and TB disease, with increased risk of maternal and infant morbidity 
and mortality, than HIV-uninfected, non-pregnant women. HIV co-infection is the 
strongest risk factor for maternal TB disease. Infants of HIV-infected mothers are at 
an increased risk of exposure to M.tb and developing active TB disease following 
infection, even if they are HIV-uninfected. Household TB contact is one of the 
greatest risks for infant M.tb infection. 
 
Currently, there are limited data on risks for M.tb infection and TB disease in  
pregnant and postpartum women, particularly those who are HIV-infected, and HIV-
exposed, uninfected infants. Therefore, determining which of these mother-infants 
pairs are at the highest risk of becoming infected with M.tb and developing TB 
disease is critical in order to reduce the burden of disease and death caused by TB in 
this population. Towards this, improved and cost-effective TB screening, particularly 
antenatal and post-partum, as well infant and household screening, active case 
finding programmes among pregnant women [4], with heightened clinical awareness 
of TB diagnosis in pregnancy and postpartum [28], improved maternal care and ART 
regimens during and after pregnancy [55] and provision of TB interventions such as 
preventive chemotherapy and new, effective TB vaccine candidates for HIV-exposed, 
uninfected infants are imperative. 




1. World Health Organization. Global tuberculosis report 2016 [Internet]. 2016. 
Available: www.who.int/tb/publications/global_report/en/ 
 




3. National Department of Health, South Africa. Joint Review of HIV, TB and 
PMTCT Programmes in South Africa - April 2014 | Health Systems Trust 




4. Bates M, Ahmed Y, Kapata N, Maeurer M, Mwaba P, Zumla A. Perspectives on 
tuberculosis in pregnancy. Int J Infect Dis. 2015;32: 124–127. 
doi:10.1016/j.ijid.2014.12.014 
 
5. Mathad JS, Gupta A. Tuberculosis in Pregnant and Postpartum Women: 
Epidemiology, Management, and Research Gaps. Clin Infect Dis Off Publ Infect 
Dis Soc Am. 2012;55: 1532–1549. doi:10.1093/cid/cis732 
 
6. World Health Organization. Tuberculosis in Women 2015 [Internet]. Available: 
www.who.int/tb 
 
7. Cotton MF, Schaaf HS, Lottering G, Weber HL, Coetzee J, Nachman S, et al. 
Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J 
Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2008;12: 225–227. 
 
8. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al. Primary 
isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J 
Med. 2011;365: 21–31. doi:10.1056/NEJMoa1011214 
 
9. Martinson NA, Moultrie H, van Niekerk R, Barry G, Coovadia A, Cotton M, et al. 
HAART and risk of tuberculosis in HIV-infected South African children: a multi- 
site retrospective cohort. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 
2009;13: 862–867. 
 
10. Lienhardt C. From exposure to disease: the role of environmental factors in 
susceptibility to and development of tuberculosis. Epidemiol Rev. 2001;23: 288– 
301. 
 
11. Marais BJ, Rabie H, Cotton MF. TB and HIV in children – advances in 
prevention and management. Paediatr Respir Rev. 2011;12: 39–45. 
doi:10.1016/j.prrv.2010.09.002 
12 Literature review  
12. Statistics South Africa. Mid-year population estimates 2015 [Internet]. Available: 
https://www.statssa.gov.za/publications/P0302/P03022015.pdf 
 
13. National Aids Council, South Africa. National Strategic Plan for HIV, TB and 
STIs 2017-2022 [Internet]. Available: http://sanac.org.za/2017/09/06/download- 
the-full-version-of-the-national-strategic-plan-for-hiv-tb-and-stis-2017-2022/ 
 
14. World Health Oganization. International Classification of diseases and related 
health problems [Internet]. 1992. Available: 
http://apps.who.int/classifications/icd10/browse/2016/en#/XV 
 
15. National Department of Health, South Africa. Saving mothers 2008-2010: Fifth 
report on the confidential enquiries into Maternal Deaths in South Africa. 
 
16. Bamford L, Stephen C, Patrick M. “Saving Children 2009”: Evaluating quality of 
care through mortality auditing. SAJCH. 2011;5: 28–32. 
 
17. National Department of Health, South Africa. National tuberculosis management 
guidelines 2014. Pretoria: Department of Health; 2014. 
 
18. National Department of Health, South Africa. The 2013 National Antenatal 
Sentinel HIV Prevalence Survey South Africa. 2015. 
 
19. Johnson LF, Stinson K, Newell M-L, Bland RM, Moultrie H, Davies M-A, et al. 
The contribution of maternal HIV seroconversion during late pregnancy and 
breastfeeding to mother-to-child transmission of HIV. J Acquir Immune Defic 
Syndr 1999. 2012;59: 417–425. doi:10.1097/QAI.0b013e3182432f27 
 
20. Goga A, Chirinda W, Bhardwaj S, Pillay Y, Sherman G, Ng’oma K, et al. 
Eliminating mother-to-child transmission of HIV in South Africa, 2002-2016: 
progress, challenges and the last mile plan. Chapter 13 SAHR 20th Ed. 2016; 
137–146. 
 
21. Goga AE, Dinh T, Jackson DJ, Lombard CJ, Puren A, Sherman G, et al. 
Population–level effectiveness of PMTCT Option A on early mother–to–child 
(MTCT) transmission of HIV in South Africa: implications for eliminating MTCT. 
J Glob Health. 2016;6. doi:10.7189/jogh.06.020405 
 
22. Mathad JS, Bhosale R, Sangar V, Mave V, Gupte N, Kanade S, et al. 
Pregnancy Differentially Impacts Performance of Latent Tuberculosis 
Diagnostics in a High-Burden Setting. PLOS ONE. 2014;9: e92308. 
doi:10.1371/journal.pone.0092308 
 
23. Hoffmann CJ, Variava E, Rakgokong M, Masonoke K, van der Watt M, 
Chaisson RE, et al. High Prevalence of Pulmonary Tuberculosis but Low 
Sensitivity of Symptom Screening among HIV-Infected Pregnant Women in 
South Africa. Cattamanchi A, editor. PLoS ONE. 2013;8: e62211. 
doi:10.1371/journal.pone.0062211 
 
24. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an 
estimate of the global burden of disease. Lancet Glob Health. 2014;2: e710– 
e716. doi:10.1016/S2214-109X(14)70330-4 
 
25. National Department of Health, South Africa. Saving Mothers 2011-2013: Sixth 
report on the confidential enquiries into maternal deaths in South Africa. 
13 Literature review  
26. Nguyen HT, Pandolfini C, Chiodini P, Bonati M. Tuberculosis care for pregnant 
women: a systematic review. BMC Infect Dis. 2014;14: 617. 
doi:10.1186/s12879-014-0617-x 
 
27. Sobhy S, Babiker Z, Zamora J, Khan K, Kunst H. Maternal and perinatal 
mortality and morbidity associated with tuberculosis during pregnancy and the 
postpartum period: a systematic review and meta-analysis. BJOG Int J Obstet 
Gynaecol. 2016; n/a-n/a. doi:10.1111/1471-0528.14408 
 
28. Bekker A, Schaaf HS, Draper HR, Kriel M, Hesseling AC. Tuberculosis Disease 
during Pregnancy and Treatment Outcomes in HIV-Infected and Uninfected 
Women at a Referral Hospital in Cape Town. PLOS ONE. 2016;11: e0164249. 
doi:10.1371/journal.pone.0164249 
 
29. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in 
pregnancy: a national, primary care-based cohort and self-controlled case 
series study. Am J Respir Crit Care Med. 2012;185: 779–784. 
doi:10.1164/rccm.201106-1083OC 
 
30. Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A, et al. Postpartum 
tuberculosis incidence and mortality among HIV-infected women and their 
infants in Pune, India, 2002-2005. Clin Infect Dis Off Publ Infect Dis Soc Am. 
2007;45: 241–249. doi:10.1086/518974 
 
31. Nachega J, Coetzee J, Adendorff T, Msandiwa R, Gray GE, McIntyre JA, et al. 
Tuberculosis active case-finding in a mother-to-child HIV transmission 
prevention programme in Soweto, South Africa. AIDS Lond Engl. 2003;17: 
1398–1400. doi:10.1097/01.aids.0000060408.18106.d9 
 
32. Lin H-C, Lin H-C, Chen S-F. Increased risk of low birthweight and small for 
gestational age infants among women with tuberculosis: Pregnancy and 
tuberculosis. BJOG Int J Obstet Gynaecol. 2010;117: 585–590. 
doi:10.1111/j.1471-0528.2010.02504.x 
 
33. Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M, Porter JDH. The 
Social Determinants of Tuberculosis: From Evidence to Action. Am J Public 
Health. 2011;101: 654–662. doi:10.2105/AJPH.2010.199505 
 
34. Seddon JA, Shingadia D. Epidemiology and disease burden of tuberculosis in 
children: a global perspective. Infect Drug Resist. 2014;7: 153–165. 
doi:10.2147/IDR.S45090 
 
35. Verver S, Warren RM, Munch Z, Richardson M, van der Spuy GD, Borgdorff 
MW, et al. Proportion of tuberculosis transmission that takes place in 
households in a high-incidence area. The Lancet. 2004;363: 212–214. 
doi:10.1016/S0140-6736(03)15332-9 
 
36. Crampin AC, Glynn JR, Traore H, Yates MD, Mwaungulu L, Mwenebabu M, et 
al. Tuberculosis transmission attributable to close contacts and HIV status, 
Malawi. Emerg Infect Dis. 2006;12: 729–735. doi:10.3201/eid1205.050789 
 
37. Middelkoop K, Mathema B, Myer L, Shashkina E, Whitelaw A, Kaplan G, et al. 
Transmission of Tuberculosis in a South African Community With a High 
Prevalence of HIV Infection. J Infect Dis. 2015;211: 53–61. 
doi:10.1093/infdis/jiu403 
14 Literature review  
38. Santin M, Muñoz L, Rigau D. Interferon-γ Release Assays for the Diagnosis of 
Tuberculosis and Tuberculosis Infection in HIV-Infected Adults: A Systematic 
Review and Meta-Analysis. PLOS ONE. 2012;7: e32482. 
doi:10.1371/journal.pone.0032482 
 
39. World Health Organization. TB/HIV Factsheet 2016 [Internet]. Available: 
www.who.int/tb/challenges/hiv/factsheets/en/ 
 
40. World Health Organization. Global tuberculosis report 2015 [Internet]. Geneva, 
Switzerland: World Health Organization; 2015. Available: 
apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf 
 
41. Gupta A, Wood R, Kaplan R, Bekker L-G, Lawn SD. Tuberculosis incidence 
rates during 8 years of follow-up of an antiretroviral treatment cohort in South 
Africa: comparison with rates in the community. PloS One. 2012;7: e34156. 
doi:10.1371/journal.pone.0034156 
 
42. Lawn SD, Myer L, Edwards D, Bekker L-G, Wood R. Short-term and long-term 
risk of tuberculosis associated with CD4 cell recovery during antiretroviral 
therapy in South Africa: AIDS. 2009;23: 1717–1725. 
doi:10.1097/QAD.0b013e32832d3b6d 
 
43. Pillay T, Khan M, Moodley J, Adhikari M, Coovadia H. Perinatal tuberculosis 
and HIV-1: considerations for resource-limited settings. Lancet Infect Dis. 
2004;4: 155–165. doi:10.1016/S1473-3099(04)00939-9 
 
44. National Department of Health, South Africa. National consolidated guidelines 
for the prevention of mother-to-child transmission of HIV (PMTCT) and the 
management of HIV in children, adolescents and adults. Pretoria: Department 
of Health; 2015. 
 
45. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. 
Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis 
Infection. Clin Microbiol Rev. 2014;27: 3–20. doi:10.1128/CMR.00034-13 
 
46. Pillay T, Sturm AW, Khan M, Adhikari M, Moodley J, Connolly C, et al. Vertical 
transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 
co-infection. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2004;8: 59– 
69. 
 
47. Jenkins HE, Yuen CM, Rodriguez CA, Nathavitharana RR, McLaughlin MM, 
Donald P, et al. Mortality in children diagnosed with tuberculosis: a systematic 
review and meta-analysis. Lancet Infect Dis. 2016; doi:10.1016/S1473- 
3099(16)30474-1 
 
48. Moyo S, Verver S, Mahomed H, Hawkridge A, Kibel M, Hatherill M, et al. Age- 
related tuberculosis incidence and severity in children under 5 years of age in 
Cape Town, South Africa. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung 
Dis. 2010;14: 149–154. 
 
49. Mahomed H, Kibel M, Hawkridge T, Schaaf HS, Hanekom WA, Iloni K, et al. 
The impact of a change in bacille Calmette-Guérin vaccine policy on 
tuberculosis incidence in children in Cape Town, South Africa. Pediatr Infect Dis 
J. 2006;25: 1167–1172. doi:10.1097/01.inf.0000243765.33880.54 
15 Literature review  
50. Wood R, Lawn SD, Caldwell J, Kaplan R, Middelkoop K, Bekker L-G. Burden of 
New and Recurrent Tuberculosis in a Major South African City Stratified by Age 
and HIV-Status. Cattamanchi A, editor. PLoS ONE. 2011;6: e25098. 
doi:10.1371/journal.pone.0025098 
 
51. Hesseling AC, Cotton MF, Jennings T, Whitelaw A, Johnson LF, Eley B, et al. 
High Incidence of Tuberculosis among HIV‐Infected Infants: Evidence from a 
South African Population‐ Based Study Highlights the Need for Improved 
Tuberculosis Control Strategies. Clin Infect Dis. 2009;48: 108–114. 
doi:10.1086/595012 
 
52. Kourtis AP, Wiener J, Kayira D, Chasela C, Ellington SR, Hyde L, et al. Health 
outcomes of HIV-exposed uninfected African infants. AIDS Lond Engl. 2013;27: 
749–759. doi:10.1097/QAD.0b013e32835ca29f 
 
53. Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new 
global challenges in the era of paediatric HIV elimination. Lancet Infect Dis. 
2016;16: e92–e107. doi:10.1016/S1473-3099(16)00055-4 
 
54. Cotton MF, Slogrove A, Rabie H. Infections in HIV-exposed Uninfected Children 
With Focus on Sub-Saharan Africa: Pediatr Infect Dis J. 2014;33: 1085–1086. 
doi:10.1097/INF.0000000000000489 
 
55. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones 
SL. HIV-exposed uninfected children: a growing population with a vulnerable 
immune system? Clin Exp Immunol. 2014;176: 11–22. doi:10.1111/cei.12251 
 
56. Bekker A, Du Preez K, Schaaf HS, Cotton MF, Hesseling AC. High tuberculosis 
exposure among neonates in a high tuberculosis and human immunodeficiency 
virus burden setting. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 
2012;16: 1040–1046. doi:10.5588/ijtld.11.0821 
 
57. Middelkoop K, Bekker L-G, Morrow C, Zwane E, Wood R. Childhood 
tuberculosis infection and disease: a spatial and temporal transmission analysis 
in a South African township. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 
2009;99: 738–743. 
 
58. Singh M, Mynak ML, Kumar L, Mathew JL, Jindal SK. Prevalence and risk 
factors for transmission of infection among children in household contact with 
adults having pulmonary tuberculosis. Arch Dis Child. 2005;90: 624–628. 
doi:10.1136/adc.2003.044255 
 
59. Bunyasi EW, Schmidt B-M, Abdullahi LH, Mulenga H, Tameris M, Luabeya A, et 
al. Prevalence of latent TB infection and TB disease among adolescents in high 
TB burden countries in Africa: a systematic review protocol. BMJ Open. 2017;7. 
doi:10.1136/bmjopen-2016-014609 
 
60. National Department of Health, South Africa. Guidelines for the management of 
Tuberculosis in children, South Africa, 2013, National Department of Health 
[Internet]. Available: www.kznhealth.gov.za/family/National-Childhood-TB- 
Guidelines-2013-ZA.pdf 
 
61. Jenum S, Selvam S, Mahelai D, Jesuraj N, Cárdenas V, Kenneth J, et al. 
Influence of Age and Nutritional Status on the Performance of the Tuberculin 
16 Literature review  
62. Skin Test and QuantiFERON-TB Gold In-Tube in Young Children Evaluated for 
Tuberculosis in Southern India: Pediatr Infect Dis J. 2014;33: e260–e269. 
doi:10.1097/INF.0000000000000399 
 
63. Adhikari M, Jeena P, Bobat R, Archary M, Naidoo K, Coutsoudis A, et al. HIV- 
Associated Tuberculosis in the Newborn and Young Infant. Int J Pediatr. 
2011;2011: 354208. doi:10.1155/2011/354208 
 
64. Seddon JA, Hesseling AC, Godfrey-Faussett P, Fielding K, Schaaf HS. Risk 
factors for infection and disease in child contacts of multidrug-resistant 
tuberculosis: a cross-sectional study. BMC Infect Dis. 2013;13: 392. 
doi:10.1186/1471-2334-13-392 
 
65. Lin H-H, Chiang Y-T, Chuang J-H, Yang S-L, Chang H-Y, Ezzati M, et al. 
Exposure to Secondhand Smoke and Risk of Tuberculosis: Prospective Cohort 
Study. PLOS ONE. 2013;8: e77333. doi:10.1371/journal.pone.0077333 
 
66. den Boon S, Verver S, Marais BJ, Enarson DA, Lombard CJ, Bateman ED, et 
al. Association between passive smoking and infection with Mycobacterium 
tuberculosis in children. Pediatrics. 2007;119: 734–739. doi:10.1542/peds.2006- 
1796 
 
67. Huang C-C, Tchetgen ET, Becerra MC, Cohen T, Galea J, Calderon R, et al. 
Cigarette smoking among tuberculosis patients increases risk of transmission to 
child contacts. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2014;18: 
1285–1291. doi:10.5588/ijtld.14.0309 
 
68. Lin H-H, Ezzati M, Murray M. Tobacco Smoke, Indoor Air Pollution and 
Tuberculosis: A Systematic Review and Meta-Analysis. Novotny TE, editor. 
PLoS Med. 2007;4: e20. doi:10.1371/journal.pmed.0040020 
 
69. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PEM, Godfrey-Faussett P, 
et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV- 
infected children. Vaccine. 2007;25: 14–18. doi:10.1016/j.vaccine.2006.07.020 
 
70. Hesseling AC, Cotton MF, Fordham von Reyn C, Graham SM, Gie RP, Hussey 
GD. Consensus statement on the revised World Health Organization 
recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc 
Lung Dis Off J Int Union Tuberc Lung Dis. 2008;12: 1376–1379. 
 
71. Nemes E, Hesseling AC, Tameris M, Mauff K, Downing K, Mulenga H, et al. 
Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, 
Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A 
Phase 2 Randomized Controlled Trial. Clin Infect Dis Off Publ Infect Dis Soc 
Am. 2017; doi:10.1093/cid/cix834 
 
72. Mofenson LM. New Challenges in the Elimination of Pediatric HIV Infection: The 





Table 1: Sample of Literature Review Matrix 
Research Question: What is the burden of and risk factors for TB in HIV-infected mothers and HIV-exposed infants in the first year of life? 






Analysis and results Comments 
Burden of TB and HIV 
WHO; Global Tuberculosis 2014, To report on the Global TB NA Data collected via data Global TB burden and HIV-TB co-infection stats were included in 
Report 2015, global TB epidemic report on  collection forms from individual proposal introduction, literature review and publication. The 
 2016 for the preceding year aspects of TB  countries, territories, WHO burden of TB, HIV and MDR-TB stats for the South Africa for the 
  of the report specifically  regions and the world preceding year of the report is provided the country profile found 
   burden of TB   in the in annexes. 
   (prevalence,    
   incidence &    
   mortality)    
National Department of 2015 To estimate Survey 33 077 Biological specimens (blood) Used for assessing the burden of HIV in women of reproductive 
Health, South Africa. The  prevalence of HIV  women processed by ELISA at central age (15-29) 
2013 National Antenatal  infection and disease  attending laboratories. Provincial and  
Sentinel HIV Prevalence  at national, provincial  antenatal National prevalence estimates  
Survey South Africa. 2015.  and district levels  clinics for the calculated  
    first time   
Burden of TB in HIV-infected pregnant and postpartum women 
Mathad JS, Gupta A. 2012 To review M.tb Review of NA Review of available literature Used for assessing the burden and risks of TB in HIV-infected 
Tuberculosis in Pregnant  infection and TB available data   pregnant and postpartum women. Future research requirements 
and Postpartum Women:  disease in pregnant and studies   highlighted. 
Epidemiology, Management,  and postpartum     
and Research Gaps. Clin  women including     
Infect Dis Off Publ Infect Dis  burden thereof, affect     
Soc Am. 2012;55: 1532–  of pregnancy on TB,     
1549.  screening, diagnosis     
  and management     
Gupta A, Nayak U, Ram M, 2007 To investigate Study 715 mothers- TST on women at routine clinic Actual data from a study rather than a review. Incidence, time 
Bhosale R, Patil S, Basavraj  postpartum TB  infant pairs visit post delivery. 24 onset and risk factors for TB disease reported 
A, et al. Postpartum  incidence and  followed up 1 developed TB = incidence of  
tuberculosis incidence and  mortality in HIV-  year post 5%. High incidence of  
mortality among HIV-  infected women-infant  delivery postpartum maternal and  
infected women and their  pairs   infant mortality. Active  
infants in Pune, India, 2002-     screening and IPT needed in  
2005. Clin Infect Dis Off     India  
Publ Infect Dis Soc Am.       
2007;45: 241–249.       
Burden of TB in HIV-exposed, uninfected infants 
Hesseling AC, Cotton MF, 2009 Estimate incidence of Prospective 245 culture- Hospital surveillance data of Indication of the high burden of TB in HIV-infected and HIV- 
Jennings T, Whitelaw A,  TB in HIV-infected Study confirmed TB annual number of culture- uninfected infants in the Western Cape Province, South Africa 
Johnson LF, Eley B, et al.  and HI-uninfected  cases confirmed TB cases among  
High Incidence of  infants in the Western  (infants) infants between 2004-2006  
Tuberculosis among  Province, South   TB Incidence 1596 cases and  
HIV‐Infected Infants:  Africa   65,9 cases per 100,000  
Evidence from a South     population among HIV-infected  
African Population‐Based     infants and HIV-uninfected  
Study Highlights the Need 
for Improved Tuberculosis 
    infants respectively Relative 
risk was 24.2 
 
Control Strategies. Clin       
 
Infect Dis. 2009;48:108114.       
Cotton MF, Schaaf HS, 2008 To determine Study 766 HIV- Household TB contact in 77 Need for TB screening of mothers at PMTCT clinics to reduce 
Lottering G, Weber HL,  incidence of TB in  exposed (10.1%) infants burden of M.tb infection and TB disease in HIV-exposed infants 
Coetzee J, Nachman S, et  HIV-exposed infants  infants (3-4   
al. Tuberculosis exposure in  after household  months old)   
HIV-exposed infants in a  exposure     
high-prevalence setting. Int       
J Tuberc Lung Dis Off J Int       
Union Tuberc Lung Dis.       
2008;12: 225–227.       
Maternal and infant risk factors for M.tb infection and TB disease 
Seddon JA, Shingadia D. 2014 Review epidemiology Review NA Analysis of available data and Comprehensive review of the risk factors for M.tb infection and 
Epidemiology and disease  of TB in children   studies TB disease in children. Good figure used in literature review 
burden of tuberculosis in       
children: a global       
perspective. Infect Drug       
Resist. 2014;7: 153–165.       
Bekker A, Schaaf HS, 2016 To investigate TB Prospective HIV-infected 74 women had TB of which Outcomes of TB in HIV-infected pregnant women and their 
Draper HR, Kriel M,  HIV-infected and cohort Study and HIV 72% were HIV-infected. All infants 
Hesseling AC. Tuberculosis  uninfected pregnant  uninfected maternal and infant deaths  
Disease during Pregnancy  women and assess  pregnant occurred in HIV-infected  
and Treatment Outcomes in  treatment outcomes  women women  
HIV-Infected and Uninfected    routinely   
Women at a Referral    admitted to a   
Hospital in Cape Town.    large referral   
PLOS ONE. 2016;11:    hospital in   
e0164249.    Cape Town   
Risk factors for M.tb infection and TB disease in HIV-exposed, uninfected infants 
Evans C, Jones CE, 2016 Review effects of HI- Review NA Increased mortality, morbidity Number of HIV-infected infants declining due to PMTCT but 
Prendergast AJ. HIV-  exposure on   due to infectious disease number of HIV-exposed, uninfected infants increasing. 
exposed, uninfected infants:  outcomes observed in   (including TB), impaired  
new global challenges in the  the increasing   growth and immune dysfuntion  
era of paediatric HIV  population of HIV-   in HIV-exposed uninfected  
elimination. Lancet Infect  exposed, uninfected   infants higher than HIV-  
Dis. 2016;16: e92–e107  infants   uninfected infants  
Afran L, Garcia Knight M, 2014 Public health question Review NA - Burden of TB in these infants and effect of maternal HIV 
Nduati E, Urban BC,  of effect of HIV and    exposure and ART on these infants 
Heyderman RS, Rowland-  ART in utero in HIV-     
Jones SL. HIV-exposed  exposed, uninfected     
uninfected children: a  infants and improved     
growing population with a  maternal     
vulnerable immune system?       
Clin Exp Immunol.       
2014;176: 11–22.       
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The Burden of Perinatal Tuberculosis in HIV-Infected Mothers and Their 1 
Infants.  2 
Katrina J Downing 3 
 4 
Abstract  5 
 6 
Background: HIV-exposed infants are at greater risk of Mycobacterium 7 
tuberculosis (M.tb) infection and tuberculosis disease (TB) compared to HIV-8 
unexposed infants. We aimed to determine the burden of, and risk factors for TB in 9 
HIV-infected mothers and their infants. 10 
 11 
Methods: Healthy, HIV-exposed South African infants and their mothers were 12 
followed for suspected TB from birth to 1 year of age in a vaccine trial. Mothers were 13 
tested at baseline for M.tb infection using the QuantiFERON-TB Gold (QFT) assay; 14 
infants were tested at 1 year. Adjusted Odds ratios (AOR) or coefficients (coef, 95% 15 
confidence intervals; CI) are reported for risk of M.tb infection and TB. 16 
 17 
Results: 248 mother-infant pairs were enrolled. Two infants were HIV-infected 18 
(<1%). Prevalence of maternal M.tb infection was 42.7% (CI 36.54 – 48.94). Mothers 19 
with CD4 count ≥350 cells/mm3 had increased odds of QFT positivity (OR 1.98, CI 20 
1.12-3.52) and for every 50 cells/mm3 increase in maternal CD4 count, maternal QFT 21 
IFN-γ values (IU/ml) increased by 17% (coef 0.155, CI 0.09-0.22). Incidence rate of 22 
maternal TB was 1.36/100 person-years (CI 0.44-4.22). Incidence rate of infant M.tb 23 
infection and TB was 2.47 (CI 1.03-5.93) and 3.62/100 person-years (CI 1.81-7.23), 24 
respectively. Infants with a new household TB contact (HHC) had increased odds of 25 
M.tb infection (OR 17.71, CI 2.5-123.5), and higher QFT values (coef 4.06, CI 2.68-26 
5.49). Infant odds of TB disease increased with higher QFT values (AOR 1.34, CI 27 
1.08-1.66), HHC (AOR 10.81, CI 1.53-76.42) and maternal smoking (AOR 10.73, CI 28 
1.96-58.89).  29 
 30 
Conclusion: Maternal CD4 count affects the QFT result and estimate of M.tb 31 
infection prevalence. Household exposure is an important driver of M.tb transmission 32 
to HIV-exposed infants. Maternal and infant improved TB screening and provision of 33 
preventive therapy are needed to reduce the burden of childhood TB in this 34 
population.  35 







Journal Ready Manuscript 2  
 43 
Introduction  44 
South Africa has one of the highest burdens of tuberculosis (TB) and HIV in the 45 
world, with an estimated incidence of 454 000 new TB cases per year and one in five 46 
of all HIV-infected people, living in South Africa [1].  47 
 48 
HIV infection, M.tb infection and TB disease are most common during a woman’s 49 
reproductive age, particularly in South African women [1]. Women aged 15 to 24 50 
years account for nearly 37% of annual new HIV infections [2]. HIV co-infection is 51 
recognized as the strongest risk factor for TB disease that either facilitates 52 
reactivation of a latent infection or favours the progression of a recently acquired 53 
infection towards active disease in HIV-infected individuals. Globally, HIV-infected 54 
adults infected with M.tb are 19 times more likely to develop TB than HIV-uninfected 55 
adults, in the absence of preventive therapy [3], which is similar in South Africa [4]. In 56 
South Africa 61% of TB cases are reported to be HIV-infected [5]. HIV-infected 57 
pregnant women with latent TB infection (LTBI) are more likely to progress to active 58 
disease [6]. The prevalence of active TB among HIV-infected, pregnant women in 59 
high TB burden countries is estimated to be 0.7-11%, compared to 0.07-0.5% in HIV-60 
uninfected women [7]. TB disease is a major cause of maternal morbidity and 61 
mortality, especially in HIV-infected women [6], accounting for 15 to 35% of maternal 62 
deaths worldwide in 2013 [8] and 26.3% of maternal deaths in South Africa between 63 
2011 and 2013 [9]. The risk of maternal morbidity in pregnant women with active TB 64 
was reported to be three times greater than pregnant women who did not have TB 65 
[9,10] and these outcomes are worse in pregnant women with TB-HIV co-infection 66 
than in those who are only TB or HIV-infected [11]. TB in pregnant women also has 67 
adverse perinatal and infant outcomes [12–14], which are higher in HIV-TB co-68 
infected women than in pregnant women infected with either TB or HIV [7].  69 
 70 
Women in the early postpartum period are twice as likely to develop TB as non-71 
pregnant women [7], within a median of 3 months post-delivery [15], possibly as a 72 
result of subclinical active TB during pregnancy, nutritional stress due to lactation, 73 
lack of sleep and rapid hormonal changes [15]. 74 
 75 
Although the number of HIV-infected infants is declining due to expanding Prevention 76 
of Mother To Child Transmission (PMTCT) programmes [16], the number of HIV-77 
exposed, uninfected infants is increasing [17]. The rate of M.tb exposure in HIV-78 
exposed, uninfected infants is high, and although data on the risk of TB in these 79 
infants are limited, they are believed to be at a high risk of developing active TB 80 
disease in high TB burden settings following infection, even if they remain HIV-81 
uninfected [18–20].  82 
 83 
Here, we report on the socio-demographic and clinical risk factors associated with 84 
M.tb infection and TB disease in a population of HIV-infected mothers and their HIV-85 
exposed infants enrolled in a Phase II TB vaccine trial conducted in TB and HIV-86 
endemic areas of South Africa.  87 
 88 
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Methods 89 
 90 
Study design and setting  91 
This analysis is based on diagnostic data from a Phase II, double blind, randomized, 92 
placebo-controlled, clinical trial to evaluate safety and immunogenicity of a novel TB 93 
vaccine, MVA85A and selective, delayed Bacille Calmette-Guerin (BCG) vaccination 94 
in infants of HIV-infected mothers. The trial was designed as a proof of concept for a 95 
novel tuberculosis vaccination strategy. Written antenatal and postnatal informed 96 
consent for infant participation was obtained from mothers. The protocol was 97 
approved by the ethics committees of the University of Cape Town (013/2012), 98 
Stellenbosch (M12/03/020) and Oxford (02-12), and the South African Medicines 99 
Control Council, and registered with Clinicaltrials.gov (NCT01650389).  It was 100 
conducted between 16 November 2012 and 12 May 2015 at two South African TB 101 
vaccine sites in the Western Cape Province; one located in a town 120km outside 102 
Cape Town (TB incidence in 2007 of 680/100 000 overall and 1500/100 000 in 103 
children younger than 2 years of age), and the other in a partially informal township 104 
located in Cape Town (TB incidence in 2009 of 1500/100 000 overall and 3290/100 105 
000 in children 18 months of age). The methodology and main results have been 106 
reported previously [21].  Briefly, infants of HIV-infected mothers were enrolled into 107 
the trial if the mothers were receiving ART or PMTCT prophylaxis, infant birth weight 108 
was >2kg and <4.5kg, and they did not have a household or frequent close contact 109 
with TB that had not yet completed TB treatment. Eligible, HIV-exposed infants 110 
(n=248) were randomized in a 1:1 ratio to receive either a single dose of MVA85A 111 
vaccine or placebo within 96 hours of birth. Since a previous study [22] had shown 112 
that MVA85A did not have any efficacy against M.tb infection or TB disease, the data 113 
from the intervention and placebo arm in this sub-analysis were analyzed together, 114 
as was data from the two sites. HIV DNA PCR testing at birth was not routine at the 115 
time of the trial. Those infants confirmed to be HIV-uninfected by HIV PCR at 6 116 
weeks of age were given BCG at 8 weeks of age and were retested for HIV at 1 year 117 
of age or after cessation of breastfeeding. Infants who were confirmed to be HIV-118 
infected by HIV PCR did not receive BCG and were followed per protocol for safety 119 
outcomes. 120 
 121 
Study procedure 122 
All participants were followed for one year for safety and immunology endpoints at 123 
scheduled visits on Days 7, 28, 42, 56, 63, 84, 112 and 365. Clinical trial staff 124 
recorded maternal and infant socio-demographic, clinical, maternal HIV data and 125 
active TB surveillance data at these visits.  126 
 127 
QuantiFERON-TB Gold In-Tube (QFT, Qiagen) was performed on all mothers at 128 
enrolment of their newborns and on infants who successfully completed one year of 129 
follow-up. At each visit, data was collected on new household or other close contact 130 
of the infant with active TB and maternal and infant symptoms suggestive of TB. 131 
Those infants with a close TB contact or who developed a positive QFT or tuberculin 132 
skin test (TST) and who were not diagnosed with TB disease were started on 133 
isoniazid (IPT), whilst infants who were diagnosed with TB were started on TB drug 134 
treatment, both as per SA and WHO guidelines. These infants remained in the trial 135 
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[21] and were included in this sub-analysis.136 
137 
Maternal and Infant M.tb infection outcomes 138 
M.tb infection in HIV-infected mothers and HIV-exposed infants is defined as a139 
positive QFT result. The QFT assay results were recorded on the trial database as140 
interferon-gamma (IFN-γ) values in IU/ml and qualitatively as positive, (TB antigen141 
minus nil IFN-γ value > 0.35 IU/ml as per the manufacturer’s instructions), negative142 
(IFN-γ value < 0.35 IU/ml) or Indeterminate. In this sub-analysis, QFT Indeterminate143 
results for both mothers and their infants were included as QFT negative results.144 
145 
Maternal and Infant TB disease outcomes 146 
Participants with suspected TB disease were investigated at local hospitals. Maternal 147 
incident TB disease was defined as mothers who received TB drug treatment. 148 
Incident TB disease was defined in infants based on the clinician’s decision to treat 149 
for TB, including microbiological (notably TST or QFT), radiological or clinical criteria 150 
for diagnosis. This definition included confirmed, unconfirmed and unlikely TB [23]. 151 
152 
Statistical analysis 153 
Statistical analysis of the dataset was performed using STATA version 12.0 154 
(DataCorp, USA).  155 
156 
The prevalence of maternal M.tb infection was estimated as number of mothers with 157 
a positive QFT at the time of enrollment divided by total number of mothers whose 158 
infants were enrolled into the study. Infant incidence rate of M.tb infection was 159 
calculated as person-years of follow-up using number of infants with a positive QFT 160 
at Day 365 divided by total number of infants who successfully completed one year of 161 
follow-up. The incidence rate of TB disease in infants and mothers was calculated as 162 
person-years of follow-up using the number of infants or mothers who were treated 163 
for TB during follow-up divided by the total number of infants who successfully 164 
completed follow-up.  165 
166 
Univariate associations of socio-demographic and clinical risk factors with maternal 167 
and infant QFT positivity and TB disease were assessed by Chi-squared or Fisher’s 168 
Exact tests and odds ratios (OR) with 95% confidence intervals (95% CI). Those risk 169 
factors with a P value <0.05 or that were deemed to be of biological precedence with 170 
or without a P value <0.25 were considered for multivariable logistic regression 171 
models to explore independent associations between these risk factors and QFT 172 
positivity or TB disease in mothers and infants. The association of risk factors with 173 
M.tb infection (measured by maternal and infant continuous QFT IFN-γ (IU/ml)174 
values) was considered in linear regression models, where non-normally distributed175 
dependent variables were log-transformed and coefficients back-transformed for176 
interpretation. Regression diagnostics were run to check whether the assumptions of177 
linearity, normality of residuals (errors), homogeneity of variance and independence178 
underlying the regression model were justified and identification of outliers and179 
influential points.180 
181 
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Additional ethics approval for this sub-analysis was granted by the University of Cape 182 
Town, Faculty of Health Sciences, Human Research Ethics Committee (UCTHREC 183 




Socio-demographic and clinical characteristics of participants188 
The 248 infants and their HIV-infected mothers enrolled in the trial were included in 189 
this sub-analysis. 190 
191 
The median age of mothers was 28.5 years; 193 (80%) of mothers were receiving 192 
lifelong ART, whilst 48 (19%) received ART prophylaxis. The median CD4 count was 193 
424 cells/mm3 (IQR 276-587), where the CD4 count was >350 cells/mm3 in 127 194 
(59.6%) mothers; 3 (1.2%) mothers reported that they were currently receiving 195 
Isoniazid Preventive Therapy (IPT); 43 (17.3%) reported having previously been 196 
treated for TB and 19 (7.7%) smoked.  197 
198 
The median gestational age of infants was 40 weeks; the median birth weight was 199 
3.2kg; 121 (49%) were male and 145 (58%) were breastfed. 217 enrolled infants 200 
completed follow-up to Day 365. Two (0.83%) infants were diagnosed as HIV PCR 201 
positive: one at 6 weeks of age and was lost to follow-up (time-on-study 111 days) 202 
and the other tested HIV PCR positive at one year of age.  203 
204 
Prevalence and demographic and clinical risk factors associated with M.tb 205 
infection in HIV-infected pregnant women 206 
Of the 248 HIV infected mothers, 106 mothers had a positive QFT result yielding a 207 
prevalence rate of maternal M.tb infection of 42.7% (95% CI 36.54 – 48.94). The 208 
maternal QFT IFN-γ (IU/ml) values were <0.35 IU/ml (57.3%), >0.35 - 0.4 IU/ml 209 
(3.2%) and > 0.4 IU/ml (39.5% (Figure 1). Since the majority of results were <0.35 210 
IU/ml and a large number were > 0.4 IU/ml, the results were further stratified as <0.2 211 
IU/ml, 0.2-0.34 IU/ml, 0.35-0.7 IU/ml and >0.7 IU/ml. Data on QFT assay imprecision, 212 
including repeatability and reproducibility, has shown that there is a zone of 213 
uncertainty (0.2 - 0.7 IU/ml), particularly around the manufacturer’s assay cutoff, 214 
indicating that a more rigorous definition for QFT-TB conversion is necessary for 215 
more definitive detection of M.tb infection [24]. 216 
217 
218 
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219 
Figure 1: QFT IFN-γ values stratified according to assay’s cutoff (0.35 IU/ml) and an uncertainty zone  220 
(0.2-0.7 IU/ml) [24]. Purple shaded bars denote low and high negative results and blue shaded bars 221 
denote low and high positive results. Maternal QFT IFN-γ results were <0.35 IU/ml (57.3%), >0.35 - 0.4 222 
IU/ml (3.2%) and > 0.4IU/ml (39.5%). The number of mothers with QFT IFN-γ <0.2 IU/ml, 0.2-0.34 IU/ml, 223 
0.35-0.7 IU/ml and >0.7 IU/ml are indicated above respective bars. 224 
225 
Mothers with a baseline CD4 count of >350 cells/mm3 had nearly double the odds of 226 
having a positive QFT result than mothers with a baseline CD4 count <350 cells/mm3  227 
(OR 1.98, 95% CI 1.12-3.52) (Table 1). Other risk factors including previous TB 228 
treatment, smoking or employment status were not associated with M.tb infection in 229 
mothers in univariate and multivariable analyses. For every 50 cells/mm3 increase in 230 
maternal CD4 count, maternal QFT IFN-γ IU/ml increased by 17% (coef 0.155, 95% 231 
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 234 
Table 1: Univariate and multivariable models of socio-demographic and clinical risk 235 
factors associated with M.tb infection (QFT positivity) in HIV-Infected mothers 236 
(n=248) 237 
 238 
* The CD4 count was recorded for 214 mothers; 7 Maternal QFT Indeterminate results included as QFT negative 239 
results; Number of observations in M.tb infection model = 213, prob>chi2=0.0209 240 
 241 
Incidence rate and demographic and clinical risk factors associated with TB 242 
disease in HIV-infected mothers 243 
Three cases of TB were diagnosed in 248 mothers, yielding an incidence rate of 244 
maternal TB disease of 1.36/100 person-years (95% CI 0.44-4.22). The median time 245 
to maternal TB diagnosis was 11.9 months (IQR 2.79-12.06) 246 
 247 
Risk factors, including maternal CD4 count >350 cells/mm3, median QFT IFN-γ 248 
values >0.4IU/ml or previous TB treatment, were not independently associated with 249 
TB disease in mothers in the univariate and multivariable analysis (Table 2).  250 
  251 
    Univariate analysis Multivariable 
analysis 










OR (95% CI) P 
value 
Age (Median; IQR) 28.5 (25-33) 28.5 (25-33) 1.01 (0.96-1.07) 0.63   
Number of other adults in household (Median, 
IQR) 
2 (2-3) 2 (2-3) 0.93 (0.74-1.18) 0.56   
Number of other children in household 
(Median, IQR) 
1 (0-2) 1 (0-2) 1.13 (0.93-1.36) 0.21   
Number of Sleeping rooms (Median, IQR) 2 (1-2) 2 (1-2) 1.05 (0.75-1.48) 0.74   
Highest Educational level (n,%) 
  Primary (Reference) 
  Junior High 
  Senior High 
      
11 (10.4%) 11 (7.9%) - - - - 
26 (24.5%) 47 (33.6%) 0.55 (0.21-1.45) 0.23   
69 (65.1%) 82 (58.6%) 0.84 (0.34-2.06) 0.70   
Employment status: (n,%) 
  Employed (=1) 
  Unemployed 
      
53 (37.3%) 42 (39.6%) 1.10 (0.66-1.85) 0.71   
89 (62.7%) 64 (60.4%)     
Employment type: (n,%) 
  Formal (Reference) 
  Informal 
  Farm 
      
22 (52.4%) 26 (49.1%)     
8 (19.1%) 6 (11.3%) 1.58 (0.47-5.23) 0.46   
12 (28.6%) 21 (39.6%) 0.68 (0.27-1.68) 0.39   
ART treatment: (n,%) 
  PMTCT  
  ART (=1) 
      
24 (22.6%) 25 (17.6%)     
82 (77.4%) 117 (82.2%) 0.73 (0.39-1.37) 0.33   
Household TB contact (baseline; n,%) 0 5 (3.5%) - -   
Previous TB Treatment (n,%) 16 (15.09%) 27 (19%) 0.76 (0.38-1.49) 0.38   




1.002 (1.00-1.003) 0.002   
CD4 count category (n, %) 
  < 350 
  > 350 (=1) 
      
29 (31.52%) 57 (47.11%)     
63 (68.48%) 64 (52.89%) 1.93 (1.10-3.41) 0.022 1.98 (1.12-3.52) 0.018 
Smokes (n, %) 9 (8.49%) 10 (7%) 1.22 (0.48-3.13) 0.67   
IPT treatment (n, %) 1 (0.95%) 2 (1.4%) 0.67 (0.06-7.52) 0.75   
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Table 2: Univariate and multivariable models of demographic and clinical risk 252 
factors associated with TB Disease in HIV-Infected mothers (n=248) 253 
* The CD4 count was recorded for 214 mothers. Number of observations in Maternal TB disease 254 
multivariable model = 213, prob>chi2=0.5782 255 
 256 
Incidence rate and demographic and clinical risk factors associated with M.tb 257 
infection in HIV-exposed infants 258 
Of the 207 infants with QFT results at Day 365, 5 were QFT positive. The incidence 259 
rate of infant M.tb infection was 2.47 per 100 person-years (95% CI 1.03 – 5.93).  260 
 261 
Nine (4.6%) infants had new HHCs, 2 (25%) of which were their mothers. Infants who 262 
had a new HHC had an 18 fold increased odds of being infected with M.tb than those 263 
infants who did not (OR 17.71, 95% CI 2.5 -123.5). Other risk factors such as living 264 
conditions, birth weight, initial feeding choice, maternal QFT status, maternal 265 
smoking or mother’s previous TB treatment were not independently associated with 266 
   Univariate analysis Multivariable analysis 
Variable name TB Disease + 
(n=3)  
 
TB Disease - 
(n=245) 




AOR (95% CI) P 
value 
Age (Median; IQR) 28 (26-33) 29 (25-33) 0.999 (0.79-1.26) 0.995   
Number of other adults in household 
(Median, IQR) 
4 (2-4) 2 (2-3) 1.58 (0.79-3.13) 0.19   
Number of other children in 
household (Median, IQR) 
1 (0-2) 1 (0-2) 1.00 (0.43-2.35) 0.997   
Number of Sleeping rooms  
(Median, IQR) 
2 (1-3) 2 (1-2) 1.51 (0.46-4.95) 0.49   
Highest Educational level: (n,%) 
  Primary (Reference) 
  Junior High 
  Senior High 
      
0 22 (9%) - -   
0 73 (30%) - -   
3 (100%) 148 (61%) - -   
Employment status: (n,%) 
  Employed (=1) 
  Unemployed 
      
2 (66.7%) 93 (38%) 3.27 (0.29-36.55) 0.34   
1 (33.3%) 152 (62%)     
Employment type: (n,%) 
  Formal (Reference) 
  Informal 
  Farm 
      
0 48 (51.6%) - -   
0 14 (15%) - -   
2 (100%) 31 (33.3%) - -   
ART treatment: (n,%) 
  PMTCT  
  ART (=1) 
      
1 (33.3%) 48 (19.6%)     
2 (66.7%) 197 (80.4%) 0.49 (0.04-5.49) 0.56   
Household TB contact (baseline; 
n,%) 
0 5 (2%) - -   
Previous TB Treatment (n,%) 1 (33.3%) 42 (17.1%) 2.42 (0.22-27.27) 0.48 4.86 (0.29-80.87) 0.27 
CD4 count (cells/mm3) (median, IQR) 215.5 (18-413) 427 (276-590) 0.99 (0.98-1.00) 0.144   
CD4 count category (n, %) 
  < 350 
  > 350 (=1) 
      
1 (50%) 85 (40.3%)     
1 (50%) 126 (59.7%) 0.68 (0.04-10.93) 0.78 0.72 (0.04-12.23) 0.82 
Smokes (n, %) 0 19 (7.8%) - - - - 
IPT treatment (n, %) 0 3 (1.2%) - - - - 
Maternal QFT + (binary; n,%) 2 (66.7%) 104 (43.7%) 2.7 (0.24-30.31) 0.42   
Maternal IFN-γ (IU/ml; median, IQR) 0.46 (-0.01–
14.41) 
0.17 (0.01–1.36) 1.16 (0.96-1.39) 0.12 0.49 (0.03-7.49) 0.61 
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positive M.tb infection in HIV-exposed infants (Table 3) in the univariate and 267 
multivariable analysis  268 
 269 
The majority of infants (n=201, 97.1%) had a QFT IFN-γ result <0.2 IU/ml, 0.48% 270 
(n=1) between 0.2 and 0.34 IU/ml and 2.42% (n=5) >0.7 IU/ml. No infants presented 271 
with QFT IFN-γ results between 0.35-0.7 IU/ml. For every new HHC, infant QFT IFN-272 
γ values (IU/ml) increased by 58 fold (coef 4.06, 95% CI 2.63-5.49), compared to 273 
QFT IFN-γ values of infants who did not have a new HHC. 274 
 275 
Incidence rate and demographic and clinical risk factors associated with TB 276 
disease in HIV-exposed infants 277 
Of 248 infants, 8 were treated for TB disease. The incidence rate of infant TB disease 278 
was 3.62 per 100 person-years (95% CI 1.81-7.23). One infant had a positive M.tb 279 
culture and 7 were diagnosed based on clinical/radiographic evidence and TB 280 
contact history. One of the TB cases was QFT positive, her mother was QFT positive, 281 
had previously been treated for TB and the infant had a new HHC that was not her 282 
mother. The median time of infant TB disease diagnosis was 8.5 months of follow-up 283 
(IQR 4.73 – 12.23). Three of the 8 infants’ mothers smoked (37.5%), although none 284 
of these mothers had TB disease.  285 
 286 
The odds of an HIV-exposed infant having TB disease were 34% greater per 1 unit 287 
(IU/ml) increase in their QFT result (AOR 1.34, 95% CI 1.08-1.66), 11 fold greater if 288 
they had a new HHC (AOR 10.81, 95% CI 1.53-76.42) compared with an infant who 289 
did not and 11 fold greater if their mother smoked (AOR 10.73, 95% CI 1.96-58.89) 290 
compared to infants whose mothers did not smoke. The odds were 20 fold greater if 291 
their mothers were receiving Izoniazid Preventive Therapy (IPT) (OR 19.83, 95% CI 292 
1.57-249.84) compared to infants whose mothers were not receiving IPT in the 293 
univariate model (Table 4). However, this was not included in the multivariable 294 
analysis as maternal IPT is a marker of maternal TB risk rather than having any 295 
causal relationship with infant TB disease. Maternal QFT status was not 296 
independently associated with having infant TB disease, nor were living conditions, 297 
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Table 3: Univariate and multivariable models of baseline demographic and 315 
clinical risk factors associated with M.tb Infection (QFT positivity) in HIV-316 
exposed infants (n=207) 317 
* 3 QFT Indeterminate results included as QFT negative results; 41 missing data points removed; Number of 318 





   Univariate  analysis Multivariable analysis 








OR (95% CI) P 
value 
Gestational age (median, IQR) 39 (39-40) 40 (39-40) 0.85 (0.45-1.59) 0.61   
Birth weight (kg; median, IQR) 3.3 (2.8-3.5) 3.2 (2.9-3.4) 1.0 (0.99-1.0) 0.63   
Length (cm; median, IQR) 50 (49-50) 49 (48-52) 0.99 (0.78-1.26) 0.95   
Head circumference (cm; median, IQR) 33 (32.5-35) 33 (32-35) 0.97 (0.58-1.62) 0.91   
Gender, male (n, %) 2 (40%) 100 (49.5%) 0.68 (0.11-4.16) 0.68   
Infant HIV-Infected 0 1 (0.5%) - -   
Number of other adults in household 
(median, IQR) 
2 (2-3) 2 (2-3) 0.90 (0.38-2.09) 0.81   
Number of other children in household 
(median, IQR) 
1 (1-1) 1 (0-2) 0.90 (0.44 -1.83) 0.77   
Number of Sleeping rooms (n,%) 2 (1-2) 2 (1-2) 0.76 (0.21-2.78) 0.67   
Educational level (n,%) 
  Primary (Reference) 
  Junior High 
  Senior High 
      
0 18 (8.9%) - -   
1 (20%) 61 (30.2%) -    
4 (80%) 123 (60.9%) -    
Employment status (n,%) 
  Employed (=1) 
  Unemployed 
      
2 (40%) 80 (39.6%) 1.02 (0.17-6.22) 0.99   
3 (60%) 122 (60.4%)     
Employment type (n,%) 
  Formal (Reference) 
  Informal 
  Farm 
      
2 (100%) 38 (47.6%) - -   
0 13 (16.3%) - -   
0 29 (36.3%) - -   
Maternal ART treatment (n,%) 
  PMTCT  
  ART(=1) 
      
1 (20%) 40 (19.8%)     
4 (80.2%) 162 (80.2%) 0.98 (0.11-9.08) 0.99   
Household TB contact (baseline; n,%) 0 5 (2.5%) - -   
New household TB contact 2 (40%) 7 (3.6%) 17.71 (2.5-123.49) 0.004 17.71 (2.54-123.49) 0.004 
Mother previously on TB treatment 
(n,%) 
2 (40%) 33 (16.3%) 3.41 (0.55-21.23) 0.18   
Mother on IPT (n,%) 0 2 (1%) - -   
Maternal CD4 count (cells/mm3; 
median, IQR) 
367.5 (299–475) 442 (278-597) 0.998 (0.99-1.00) 0.57   
Maternal CD4 count category (n,%) 
  <350 
  >350 (=1) 
      
2 (50%) 67 (38.7%)     
2 (50%) 106 (61.3%) 0.63 (0.087-4.59) 0.65   
Maternal Smoking (n, %) 0 17 (8.4%) - -   
Initial feeding Choice (n,%) 
  Breast feeding (=1) 
  Formula Feeding 
      
4 (80%) 122 (60,40%) 2.62 (0.29-23.90) 0.392   
1 (20%) 80 (39.6%)     
Maternal TB disease (n, %) 0 3 (1.5%) - -   
Maternal QFT +ve (binary; n,%) 2 (40%) 91 (45.1%) 0.81 (0.13-4.97) 0.82   
Maternal  IFN-γ (IU/ml; median, IQR) 0.27 (0.06-0.46) 0.2 (0.01-1.39) 0.95 (0.60-1.23) 0.99   
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 324 
Table 4. Univariate and multivariable models of baseline demographic and 325 
clinical risk factors associated with TB Disease in HIV exposed infants (n=248) 326 
* Number of observations in Infant TB disease multivariable model = 198, prob>chi2=0.0022 327 
 328 
 329 
   Univariate analysis Multivariate analysis 
Variable name TB Disease + 
(n=8) 
TB Disease - 
(n=240) 




AOR (95% CI) P 
value 
Gestational age (median, IQR) 40 (39-40.5) 40(39-40) 1.17 (0.69-1.95) 0.55   
Birth weight (kg; median, IQR) 3.4 (3.2-3.6) 3.2 (2.9-3.4) 1.00 (0.99-1.00) 0.22   
Length (cm; median, IQR) 51 (50-54.5) 49 (48-52) 1.18 (1.00-1.39) 0.05   
Head circumference (cm; median, 
IQR) 
33 (32-35) 33 (32-35) 0.84 (0.56-1.27) 0.42   
Gender, male (n, %) 4 (50%) 117 (48.8%) 1.05 (0.26-4.30) 0.95   
Infant HIV-Infected 0 2 (0.83%) - -   
Number of other adults in household  
(median, IQR) 
3 (2-3) 2 (2-3) 1.22 (0.71-2.08) 0.47   
Number of other children in household  
(median, IQR) 
1 (1) 1 (0-2) 0.80 (0.43-1.48) 0.48   
Sleeping rooms (n, %) 1 (1-2) 2 (1-2) 0.44 (0.13-1.57) 0.28   
Educational level (n,%) 
  Primary (Reference) 
  Junior High 
  Senior High 
      
1 (12.5%) 21 (8.9%)     
4 (50%) 67 (28.5%) 1.22 (0.131-1.49) 0.86   
3 (37.50%) 149 (62.6%) 0.43 (0.04-4.3) 0.47   
Employment status (n,%) 
  Employed (=1) 
  Unemployed 
      
3 (37.5%) 92 (38.3%) 0.97 (0.23-4.13) 0.96   
5 (62.5%) 148 (61.7%)     
Employment type (n,%) 
  Formal (Reference) 
  Informal 
  Farm 
      
1 (33.3%) 46 (51.1%)     
1 (33.3%) 13 (14.13%) 3.61 (0.21-61.82) 0.38   
1 (33.3%) 32 (34.78%) 1.47 (0.09-24.35) 0.79   
Maternal ART treatment (n,%) 
  PMTCT  
  ART (=1) 
      
2 (25%) 47 (19.6%)     
6 (75%) 193 (80.4%) 0.73 (0.14-3.7) 0.76   
Baseline household TB contact (n,%) 0 5 (2.1%) - -   
New household TB contact 2 (25%) 7 (3.5%) 9.09 (1.55-53.35) 0.014 10.81 (1.52-76.43) 0.017 
Mother previously on TB treatment 
(n,%) 
2 (25%) 41 (17.0%) 1.61 (0.32-8.30) 0.56   
Mother on IPT (n,%) 1 (14.3%) 2 (0.8%) 19.8 (1.57-249.85) 0.02   
Maternal CD4 count (median, IQR) 425.5 
 (320 – 670) 
424 
(271-587) 
1.00 (0.99-1.00) 0.25   
CD4 count category (n,%) 
  <350 
  >350 (=1) 
      
3 (37.5%) 83 (40.5%)     
5 (62.5%) 122 (59.5%) 1.13 (0.26-4.87) 0.87   
Maternal smoking (n, %) 3 (37.5%) 16 (6.7%) 8.4 (1.83-38.35) 0.006 10.73 (1.96-58.89) 0.006 
Initial feeding Choice (n,%) 
  Breast feeding (=1) 
  Formula Feeding 
      
5 (62.5%) 141 (58.75%) 1.17 (0.27-5.01) 0.83   
3 (37.5%) 99 (41.25%)     
Maternal TB disease (n, %) 0 3 (1.3%) - -   
Maternal QFT + (binary; n,%) 3 (37.5%) 103 (42.9%) 0.79 (0.19-3.42) 0.76   
Maternal IFN-γ (IU/ml; median,IQR) 0.04 (0-3.89) 0.19 (0.01-1.31) 1.01 (0.83-1.24) 0.90   
Infant QFT + (binary, n,%) 2 (25%) 3 (1.51%) 21.78 (3.05-155.37) 0.002   
Infant IFN-γ (IU/ml; median,IQR) 0.01 (-0.005-0.47) 0 (-0.02-0.02) 1.27 (1.03-1.57) 0.02 1.34 (1.08-1.66) 0.009 
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Discussion 330 
We have shown that in a cohort of HIV-exposed South African infants and their HIV-331 
infected mothers who were actively followed for one year, maternal CD4 count >350 332 
cells/mm3 was strongly associated with QFT positivity that may have affected the 333 
estimate of maternal M.tb infection. Infant M.tb infection was driven by new 334 
household TB contact as was infant TB disease in addition to higher QFT values 335 
(IU/ml) and maternal smoking.  336 
 337 
Although maternal M.tb infection (identified as QFT positivity) in HIV-infected mothers 338 
was high (42.7%), it was considerably lower than that previously observed in HIV 339 
uninfected, young adults in the community (52-60%) [25]. The maternal median CD4 340 
count in this study was relatively high (424 cells/mm3) due to the inclusion criterion for 341 
enrollment of maternal lifelong ART or perinatal ART prophylaxis. The prevalence of 342 
QFT positivity was strongly associated with maternal CD4 count > 350 cells/mm3, 343 
possibly suggesting impaired sensitivity of QFT in those with lower CD4 counts. 344 
Studies on performance of the QFT assay in HIV-infected individuals have shown 345 
that the sensitivity of QFT is lower in HIV-infected individuals, increasing with 346 
increasing CD4 cell count [26]. QFT relies on functional CD4 cells and its 347 
performance can negatively be influenced by low and impaired CD4 cell counts in 348 
HIV-infected individuals. This inclusion criterion may also explain the low (<1%) infant 349 
HIV acquisition in this study, which is considerably lower than the perinatal HIV 350 
transmission rates in South Africa at the time of the trial (2.7% in 2012) [27].  351 
 352 
The incidence rate of maternal TB disease in this study was 1.36 cases/100 person-353 
years. This is similar to TB incidence rates among patients receiving ART, with the 354 
highest and lowest rates in patients with CD4 counts <100 and > 500 cells/ mm3 355 
respectively [28]. In patients with CD4 counts of 401-500 cells/mm3, the incidence 356 
rate was 1.5 cases/100 person years [28]. A recent study showed that the TB rate 357 
was greater in HIV-infected persons on ART at 2.70-25.49 cases per person-years, 358 
than in HIV-uninfected persons living in the same community [29].  359 
 360 
Interestingly, the incidence rate of QFT positivity in HIV-exposed infants at one year 361 
of age (2.5%) is lower than that reported for HIV-unexposed infants in this community 362 
of 6-7% [22,25], whereas the incidence of TB disease in infants of 3.6% was similar 363 
to that reported previously for these communities [22]. In a study in the Western 364 
Cape Province, South Africa the potential incidence of TB exposure was 10.03%, 365 
with a predicted possible infection rate of 5.01% and a rate of disease of 2.01% [18]. 366 
The interpretation of our findings was likely to have been limited by the exclusion 367 
criterion for enrolment of mothers with active TB who had not yet completed TB 368 
treatment as well as maternal household TB contact(s), which could have reduced 369 
the risk of M.tb transmission and TB disease in mothers and their infants.  370 
 371 
We have shown in this study that a new household contact is independently 372 
associated with M.tb infection and TB disease in infants, with 2 of the 9 household 373 
contacts being the mother. This finding is supported by reports that the majority of 374 
children younger than 2 years of age are infected from a household sputum smear-375 
positive source case [30–32], usually the mother or father. The greater the daily 376 
interaction and the longer the duration of contact with the source case, the greater 377 
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the risk of infection [30]. In particular, HIV-exposed infants are at an increased risk of 378 
exposure to M.tb and are at a high risk of developing active TB disease following 379 
infection [18], whether they are HIV-infected or not [19]. Cotton et al (2008) [18] 380 
reported that 10.1% HIV-exposed infants  in their study had household TB contacts 381 
(mothers or fathers) as well as close TB contacts outside of the house. 382 
 383 
Andrews et al (2017) [33], found that very high IFN-γ values above the highest value 384 
of the standard curve of the QFT assay were a reliable estimate of the true IFN-γ 385 
values up to about 12.00 IU/ml in young children. They also found that the incidence 386 
rate of TB disease was significantly higher in children with very high QFT IFN-γ 387 
values (>4.0 IU/ml). These results indicated that QFT IFN-γ values much higher than 388 
the manufacturer’s recommended cutoff value of 0.35 IU/ml were clinically useful. In 389 
our sub-analysis, IFN-γ values for QFT positive infants were above 0.7 IU/ml, and 2 390 
values higher than 12.00 IU/ml were removed from the infant QFT data for the linear 391 
regression analysis.  392 
 393 
A limited number of studies have shown that tobacco/cigarette smoke exposure is 394 
associated with M.tb infection in children who are in contact with a patient with TB 395 
disease [34–36]. In this analysis, 3 of the 8 infants with TB disease had mothers who 396 
smoked, although none of these mothers had TB disease. Clinical diagnosis of infant 397 
TB disease in this sub-analysis may have been an overestimation of the true disease 398 
rate [21], where clinicians may have diagnosed TB disease in infants with impaired 399 
clearance of mucosal secretions or decrease in immune response [37] or reactive 400 
airways reactive airways.  401 
 402 
At the time of the trial, the South African TB Preventive therapy guidelines (2010) 403 
recommended that all HIV-infected people regardless of TST status receive 6 months 404 
of IPT [38], which were revised in 2013 to recommend at least 36 months of IPT to 405 
TST-positive persons or 6 months of IPT if TST status is unknown [39]. Many studies 406 
have shown that treatment for latent TB infection significantly reduces the risk of 407 
active TB disease in HIV-infected persons, particularly if taken for 36 months 408 
[38,40,41], although this TB prevention benefit declined after cessation of IPT [42]. 409 
Despite these recommendations, routine screening for active TB, provision and 410 
monitoring of IPT to HIV-infected pregnant women at PMTCT antenatal clinics is 411 
suboptimal [39,42]. Notably only 3 (1.21%) of the mothers reported receiving IPT at 412 
baseline, 1 of which was QFT positive and did not have TB disease. It is unclear why 413 
this was independently associated with infant TB disease but could possibly be due 414 
to potential bias as a result of selection of high-risk mothers for IPT. 415 
 416 
Interpretation of our findings could be limited by the study population and sample size 417 
that was originally selected to assess the safety and immunogenicity of the MVA85A 418 
vaccine [21] and not powered to accurately assess M.tb incidence rate and TB 419 
disease and their risk factors. The small number of incident cases of maternal TB 420 
disease, infant QFT positivity and TB disease limited the precision of estimates of 421 
these outcomes and of identifying precise estimates of the effect of different risk 422 
factors on the outcomes. Further, infants with low birth weight or born preterm, 423 
outcomes that could have resulted from mothers with untreated TB during pregnancy 424 
[13,14], were excluded from the study. Most children who progress to disease do so 425 
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within 12 months of being infected, it being estimated that 50% of infants whose 426 
mothers have active TB disease will develop TB disease during the first year of life 427 
[43]. Since children from 1-2 years of age have a 20 -30% risk of developing disease 428 
[44], the number of cases of M.tb infection and TB disease in infants and their 429 
mothers may have been higher if the cohort was followed for an additional 12 430 
months.  431 
 432 
In conclusion, maternal CD4 count affects the QFT value and may have affected the 433 
estimate of maternal M.tb infection. Household exposure is an important driver of 434 
M.tb transmission to HIV-exposed infants with low risk of HIV acquisition. 435 
Determining pregnant or postpartum HIV-infected mothers and their infants who are 436 
at the greatest risk of M.tb exposure, infection and TB disease is critical to reduce the 437 
burden of disease and death caused by TB in this population.  438 
 439 
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APPENDIX A: ADDITIONAL DISSERTATION ANALYSIS 
 
APPENDIX A1: Multivariable linear regression of demographic and clinical risk 
factors associated with M.tb infection in HIV-infected mothers 
 
 
1. Linear regression model 1: Simple model with just one variable: Maternal 
QFT IFN-γ (dependent); Maternal CD4 count per 50 cells/mm3 
 
xi:regress MumQFTtbagnil cd4_50 
 
 
Source | SS df MS Number of obs = 213 
-------------+------------------------------ F( 1, 211) = 14.53 
Model | 147.345951 1 147.345951 Prob > F = 0.0002 
Residual | 2139.03522 211 10.1376077 R-squared = 0.0644 
-------------+------------------------------ Adj R-squared = 0.0600 
Total | 2286.38117 212 10.7848168 Root MSE = 3.184 
 
------------------------------------------------------------------------------ 
MumQFTtbag~l | Coef. Std. Err. t P>|t| [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
cd4_50 | .1887015 .0494964 3.81 0.000 .0911306 .2862723 





    
 
 
Shapiro-Wilk W test for normal data 
Variable | Obs W V z Prob>z 
-------------+-------------------------------------------------- 











The residuals are not normally distributed as the p value is less than 0.05 therefore 
don’t have enough evidence to reject the null hypothesis which is that variable is 
normally distributed. 
 
2. Linear regression model 2: Simple model with the dependent variable 
(Maternal QFT IFN-γ) log transformed (natural log) and Maternal CD4 count 
 
 
Source | SS df MS Number of obs = 170 
-------------+------------------------------ F( 1, 168) = 14.85 
Model | 57.2200388 1 57.2200388 Prob > F = 0.0002 
Residual | 647.265005 168 3.85276789 R-squared = 0.0812 
-------------+------------------------------ Adj R-squared = 0.0758 
Total | 704.485044 169 4.16855056 Root MSE = 1.9628 
 
------------------------------------------------------------------------------ 
MumQFTtbag~n | Coef. Std. Err. t P>|t| [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
MumCD4Count | .0025877 .0006715 3.85 0.000 .0012621 .0039133 
_cons | -2.116279 .3371543 -6.28 0.000 -2.781884 -1.450674 
------------------------------------------------------------------------------ 
 
2.1 Checking for normality of residuals 
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Shapiro-Wilk W test for normal data 
 




res13 | 170 0.98005 2.585 2.167 0.01510 
 
Residuals still not completely normally distributed 
 























































Scatter is random/does not have a pattern and so it is ok. 
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2.4 Checking for collinearity 
 
The mean VIF is 1.00 but don’t need to do this as there is only one variable 
 




| MumCD4~t resstud2 | 
|----------------------| 
1. | 413 . | 
3. | . . | 
6. | 255 . | 
7. | 391 . | 
12. | 565 -2.039305 | 
|----------------------| 
14. | 359 . | 
32. | 442 . | 
35. | 333 . | 
39. | 242 . | 
40. | 431 . | 
|----------------------| 
41. | 205 . | 
48. | 242 . | 
49. | 167 . | 
57. | . . | 
59. | . . | 
|----------------------| 
61. | 263 . | 
66. | 255 . | 
71. | 616 . | 
74. | 306 . | 
76. | 224 . | 
|----------------------| 
80. | 52 2.061417 | 
83. | 607 -2.098317 | 
84. | 341 . | 
90. | 498 . | 
92. | 480 . | 
|----------------------| 
95. | 424 . | 
97. | 196 . | 
101. | 874 . | 
103. | 427 . | 
107. | . . | 
|----------------------| 
111. | . . | 
114. | 175 . | 
120. | . . | 
138. | 694 . | 
139. | . . | 
|----------------------| 
145. | . . | 
147. | . . | 
149. | . . | 
153. | 130 . | 
154. | . . | 
|----------------------| 
155. | 865 . | 
157. | . . | 
158. | . . | 
160. | 200 . | 
163. | . . | 
|----------------------| 
164. | . . | 
165. | 852 . | 
168. | 380 . | 
170. | . . | 
171. | 380 . | 
|----------------------| 
173. | . . | 
 
175. | . . | 
176. | 507 . | 
183. | . . | 
185. | 527 . | 
|----------------------| 
186. | 883 . | 
189. | . . | 
195. | . . | 
197. | 417 . | 
205. | 598 . | 
|----------------------| 
206. | 195 . | 
207. | 346 . | 
211. | 174 . | 
213. | . . | 
217. | 622 . | 
|----------------------| 
218. | 622 . | 
220. | . . | 
224. | . . | 
225. | . . | 
226. | 396 . | 
|----------------------| 
227. | . . | 
228. | . . | 
230. | . . | 
231. | . . | 
233. | . . | 
|----------------------| 
241. | . . | 
242. | . . | 
244. | . . | 
245. | 545 . | 
247. | . . | 
|----------------------| 







































| lev2 | 
|----------| 
1. | .0060364 | 
2. | .0098753 | 
3. | . | 
4. | .0113565 | 
5. | .0075754 | 
|----------| 
6. | .0102995 | 
7. | .0062799 | 
8. | .0276494 | 
9. | .0123846 | 
10. | .0075196 | 
|----------| 
11. | .0095784 | 
12. | .0074494 | 
13. | .0082848 | 
14. | .0068362 | 
15. | .0146221 | 
|----------| 
16. | .0058836 | 
17. | .0088888 | 
18. | .0331509 | 
19. | .0072545 | 
20. | .0193879 | 
|----------| 
21. | .0058824 | 
22. | .0080878 | 
23. | .0062272 | 
24. | .0096019 | 
25. |  .007492 | 
|----------| 
26. | .0200775 | 
91. | .0149081 | 
 
28. | .0147505 | 
29. | .0072545 | 
30. | .0066638 | 
|----------| 
31. | .0123846 | 
32. | .0058886 | 
33. | .0096201 | 
34. | .0102542 | 
35. | .0074647 | 
|----------| 
36. | .0069672 | 
37. | .0058958 | 
38. | .0118216 | 
39. | .0109104 | 
40. | .0059215 | 
|----------| 
41. | .0128656 | 
42. | .0058904 | 
43. | .0164344 | 
44. | .0058958 | 
45. | .0075317 | 
|----------| 
46. | .0059134 | 
47. | .0112557 | 
48. | .0109104 | 
49. | .0152072 | 
50. | .0088514 | 
|----------| 
51. | .0081019 | 
52. | .0063427 | 
53. | .0091742 | 
54. | .0077191 | 
55. | .0060578 | 
|----------| 
56. | .0174733 | 
57. | . | 
58. | .0138104 | 
59. | . | 
60. |  .005887 | 
|----------| 
61. | .0099432 | 
62. | .0059044 | 
63. | .0087565 | 
64. | .0165754 | 
65. | .0124157 | 
|----------| 
66. | .0102995 | 
67. | .0074107 | 
68. | .0111063 | 
69. | .0106235 | 
70. | .0121116 | 
|----------| 
71. |  .009135 | 
72. | .0069226 | 
73. | .0085961 | 
74. | .0082848 | 
75. | .0099869 | 
|----------| 
76. | .0118216 | 
77. | .0074224 | 
78. | .0082182 | 
79. | .0059857 | 
80. | .0243527 | 
|----------| 
81. | .0065183 | 
82. | .0061118 | 
83. | .0087933 | 
84. | .0072545 | 
85. | .0085055 | 
|----------| 
86. | .0067422 | 
87. | .0068362 | 
88. |  .006435 | 
89. | .0093962 | 
90. | .0061601 | 
|----------| 
 
92. | .0059928 | 
93. | .0061954 | 
94. | .0060722 | 
95. | .0059572 | 
|----------| 
96. | .0069226 | 
97. | .0133897 | 
98. | .0076447 | 
99. | .0059572 | 
100. | .0093156 | 
|----------| 
101. | .0269918 | 
102. | .0065892 | 
103. | .0059405 | 
104. | .0187593 | 
105. | .0078081 | 
|----------| 
106. |  .009333 | 
107. | . | 
108. | .0096621 | 
109. | .0082514 | 
110. | .0080241 | 
|----------| 
111. | . | 
112. | .0066448 | 
113. | .0058947 | 
114. | .0146862 | 
115. | .0058827 | 
|----------| 
116. | .0103451 | 
117. | .0114582 | 
118. | .0127198 | 
119. | .00622 | 
120. | . | 
|----------| 
121. | .0058886 | 
122. | .0059539 | 
123. | .0058827 | 
124. | .0202767 | 
125. | .0059659 | 
|----------| 
126. |  .010739 | 
127. | .0188032 | 
128. | .0058824 | 
129. | .0059928 | 
130. | .0111559 | 
|----------| 
131. | .0059969 | 
132. | .0062722 | 
133. |  .023474 | 
134. | .0084359 | 
135. | .0103909 | 
|----------| 
136. | .0088303 | 
137. | .0083672 | 
138. | .0128906 | 
139. | . | 
140. | .0065711 | 
|----------| 
141. | .0072402 | 
142. | .0149081 | 
143. | .0082182 | 
144. | .0079925 | 
145. | . | 
|----------| 
146. | .0242075 | 
147. | . | 
148. | .0126952 | 
149. | . | 
150. | .0100309 | 
|----------| 
151. | .0134491 | 
152. | .0134491 | 
153. |  .017812 | 
154. | . | 
155. | .0261066 | 
|----------| 
 
156. | .0063575 | 
157. | . | 
158. | . | 
159. | .0058832 | 
160. | .0131544 | 
 |----------| 
161. | .0258158 | 
162. | .0210725 | 
163. | . | 
164. | . | 
165. | .0248615 | 
 |----------| 
166. | .0081996 | 
167. | .0121422 | 
168. | .0064441 | 
169. | .0058827 | 
170. | . | 
 |----------| 
171. | .0064441 | 
172. | .0126952 | 
173. | . | 
174. | .0093962 | 
175. | . | 
 |----------| 
176. | .0062722 | 
177. | .0059375 | 
178. | .0091571 | 
179. | .0076899 | 
180. | .0062858 | 
 |----------| 
181. | .0113786 | 
182. | .0092135 | 
183. | . | 
184. | .0119808 | 
185. | .0065892 | 
 |----------| 
186. | .0278959 | 
187. | .0065711 | 
188. | .006086 | 
189. | . | 
190. | .0063281 | 
 |----------| 
191. | .0144588 | 
192. | .0138369 | 
193. | .0150101 | 
194. | .0069448 | 
195. | . | 
 |----------| 
196. | .0074647 | 
197. | .0060043 | 
198. | .0109104 | 
199. | .0072043 | 
200. | .0078383 | 
 |----------| 
201. | .0073056 | 
202. | .0417624 | 
203. | .0098997 | 
204. | .0101389 | 
205. | .0084706 | 
 |----------| 
206. | .0134491 | 
207. | .0071307 | 
208. | .0259672 | 
209. | .0661637 | 
210. | .0067739 | 
 |----------| 
211. | .0147505 | 
212. | .0087933 | 
213. | . | 
214. | .0230232 | 
215. | .0067222 | 
 |----------| 
216. | .0136287 | 
217. | .0093734 | 
218. | .0093734 | 
219. | .0579011 | 
220. | . | 
 
 |----------| 
221. | .0117918 | 
222. | .0082848 | 
223. | .0103193 | 
224. | . | 
225. | . | 
 |----------| 
226. | .0062146 | 
227. | . | 
228. | . | 
229. | .0133563 | 
230. | . | 
 |----------| 
231. | . | 
232. | .0152734 | 
233. | . | 
234. | .0267934 | 
235. | .0382254 | 
 |----------| 
236. | .025104 | 
237. | .0087773 | 
238. | .0062663 | 
239. | .0227169 | 
240. | .0850919 | 
 |----------| 
241. | . | 
242. | . | 
243. | .007661 | 
244. | . | 
245. | .0069545 | 
 |----------| 
246. | .006428 | 
247. | . | 





























2.6.2 Cook’s Distance 
 
+----------+ 
|  cooksd2 | 
|----------| 
1. | . | 
 
2. | .0098374 | 
3. | . | 
4. | .0045886 | 
5. | .0074421 | 
|----------| 
6. | . | 
7. | . | 
8. | .0063467 | 
9. | .0003408 | 
10. | .0081672 | 
|----------| 
11. | .0068184 | 
12. | .0153183 | 
13. | .0000393 | 
14. | . | 
15. | .0032511 | 
|----------| 
16. | .0040208 | 
17. |  .002452 | 
18. |  .005975 | 
19. | .0023833 | 
20. | .0016229 | 
|----------| 
21. | .0102953 | 
22. | .01323 | 
23. | .0100875 | 
24. | .0048671 | 
25. | .0037984 | 
|----------| 
26. |  .005048 | 
27. | .0002528 | 
28. | 6.31e-06 | 
29. |  .003764 | 
30. | .0028288 | 
|----------| 
31. | .0001586 | 
32. | . | 
33. | .0020879 | 
34. | .0014646 | 
35. | . | 
|----------| 
36. | .0000399 | 
37. | .0012618 | 
38. | .0147933 | 
39. | . | 
40. | . | 
|----------| 
41. | . | 
42. | .0083456 | 
43. | .0069527 | 
44. | .0017349 | 
45. | .0006406 | 
|----------| 
46. | .0009819 | 
47. | 4.11e-06 | 
48. | . | 
49. | . | 
50. | .0053585 | 
|----------| 
51. |  .001317 | 
52. | .0100521 | 
53. | .0108194 | 
54. | .0011318 | 
55. | .0028539 | 
|----------| 
56. | .0036528 | 
57. | . | 
58. | .0046686 | 
59. | . | 
60. | .0016996 | 
|----------| 
61. | . | 
62. | .0003082 | 
63. | .0002035 | 
64. | .0200559 | 
65. | .0152682 | 
|----------| 
130. | .0025425 | 
 
66. | . | 
67. | .0000506 | 
68. | .0018798 | 
69. | .0011275 | 
70. | .0203589 | 
|----------| 
71. | . | 
72. | 7.21e-06 | 
73. | .0074633 | 
74. | . | 
75. | .0105935 | 
|----------| 
76. | . | 
77. | .0012414 | 
78. | .0092366 | 
79. | .0030263 | 
80. | .0520278 | 
|----------| 
81. | .0030821 | 
82. | .0047738 | 
83. | .0191422 | 
84. | . | 
85. | .0010088 | 
|----------| 
86. | .0002073 | 
87. | .0037123 | 
88. | .0003305 | 
89. | .0002067 | 
90. | . | 
|----------| 
91. | .0177508 | 
92. | . | 
93. | .0011956 | 
94. |  .006498 | 
95. | . | 
|----------| 
96. | .0008651 | 
97. | . | 
98. | .0012997 | 
99. | .0000127 | 
100. | .0077921 | 
|----------| 
101. | . | 
102. | .0018337 | 
103. | . | 
104. |  .008374 | 
105. | .0003079 | 
|----------| 
106. | .0013641 | 
107. | . | 
108. | .0003305 | 
109. | .0073043 | 
110. | .0064726 | 
|----------| 
111. | . | 
112. |  .001303 | 
113. | .0096615 | 
114. | . | 
115. | .0018775 | 
|----------| 
116. | .0015598 | 
117. | 3.63e-06 | 
118. | .0022067 | 
119. | .0022304 | 
120. | . | 
|----------| 
121. | .0003486 | 
122. | .0091558 | 
123. |  .000081 | 
124. | .0007808 | 
125. | .0000728 | 
|----------| 
126. | .0081134 | 
127. | .0195422 | 
128. | .0039701 | 
129. | .0035428 | 
194. | .0006945 | 
 
 |----------| 
131. | .0001259 | 
132. | .0037818 | 
133. | .0059631 | 
134. | .0000133 | 
135. | .0015068 | 
 |----------| 
136. | .0013267 | 
137. | .005525 | 
138. | . | 
139. | . | 
140. | .0011773 | 
 |----------| 
141. | .0009201 | 
142. | .0156048 | 
143. | .0065803 | 
144. | .001057 | 
145. | . | 
 |----------| 
146. | .0274933 | 
147. | . | 
148. | .004048 | 
149. | . | 
150. | .0000375 | 
 |----------| 
151. | .0160697 | 
152. | .0160697 | 
153. | . | 
154. | . | 
155. | . | 
 |----------| 
156. | .0107901 | 
157. | . | 
158. | . | 
159. | .0060832 | 
160. | . | 
 |----------| 
161. | .0019814 | 
162. | .0004953 | 
163. | . | 
164. | . | 
165. | . | 
 |----------| 
166. | .0018496 | 
167. | .000078 | 
168. | . | 
169. | .0039794 | 
170. | . | 
 |----------| 
171. | . | 
172. | .0000902 | 
173. | . | 
174. | .00017 | 
175. | . | 
|----------| 
176. | . | 
177. | .0000114 | 
178. | .0001798 | 
179. | .0013608 | 
180. | .0068814 | 
 |----------| 
181. | .006873 | 
182. | .0088913 | 
183. | . | 
184. | .0076861 | 
185. | . | 
|----------| 
186. | . | 
187. | .0018221 | 
188. | .0056607 | 
189. | . | 
190. | .0001488 | 
 |----------| 
191. | .0006554 | 
192. | .0008106 | 
193. | .0172225 | 
 
195. | . | 
|----------| 
196. | .0049871 | 
197. | . | 
198. | .009421 | 
199. | .0117343 | 
200. | .0034407 | 
 |----------| 
201. | .0025171 | 
202. | .0712725 | 
203. | .0131868 | 
204. | .0054703 | 
205. | . | 
 |----------| 
206. | . | 
207. | . | 
208. | .0033423 | 
209. | .0371318 | 
210. | 7.78e-06 | 
 |----------| 
211. | . | 
212. | .0094021 | 
213. | . | 
214. | .008173 | 
215. | .0078325 | 
 |----------| 
216. | .0034434 | 
217. | . | 
218. | . | 
219. | .0086098 | 
220. | . | 
 |----------| 
221. | .000511 | 
222. | .0030536 | 
223. | .0000949 | 
224. | . | 
225. | . | 
 |----------| 
226. | . | 
227. | . | 
228. | . | 
229. | .0018437 | 
230. | . | 
|----------| 
231. | . | 
232. | .0284476 | 
233. | . | 
234. | .0005188 | 
235. | .0156954 | 
 |----------| 
236. | .0009387 | 
237. | .000425 | 
238. | 9.54e-06 | 
239. | .0120633 | 
240. | .0018495 | 
 |----------| 
241. | . | 
242. | . | 
243. | .0007253 | 
244. | . | 
245. | . | 
 |----------| 
246. | .0001939 | 
247. | . | 



























| dfMumCD~t | 
|-----------| 
1. | . | 
3. | . | 
6. | . | 
7. | . | 
14. | . | 
|-----------| 
32. | . | 
35. | . | 
39. | . | 
40. | . | 
41. | . | 
|-----------| 
48. | . | 
49. | . | 
57. | . | 
59. | . | 
61. | . | 
|-----------| 
64. | -.1615313 | 
66. | . | 
70. | -.14573 | 
71. | . | 
74. | . | 
|-----------| 
76. | . | 
80. |  -.283633 | 
84. | . | 
90. | . | 
91. | -.1472014 | 
|-----------| 
92. | . | 
95. | . | 
97. | . | 
101. | . | 
103. | . | 
 
|-----------| 
107. | . | 
111. | . | 
114. | . | 
120. | . | 
127. | -.1643942 | 
 |-----------| 
138. | . | 
139. | . | 
142. | .1378987 | 
145. | . | 
146. | .2047692 | 
 |-----------| 
147. | . | 
149. | . | 
153. | . | 
154. | . | 
155. | . | 
|-----------| 
157. | . | 
158. | . | 
160. | . | 
163. | . | 
164. | . | 
|-----------| 
165. | . | 
168. | . | 
170. | . | 
171. | . | 
173. | . | 
|-----------| 
175. | . | 
176. | . | 
183. | . | 
185. | . | 
186. | . | 
|-----------| 
189. | . | 
193. | .1452773 | 
195. | . | 
197. | . | 
202. | -.3523567 | 
 |-----------| 
205. | . | 
206. | . | 
207. | . | 
209. | .260155 | 
211. | . | 
|-----------| 
213. | . | 
217. | . | 
218. | . | 
220. | . | 
224. | . | 
|-----------| 
225. | . | 
226. | . | 
227. | . | 
228. | . | 
230. | . | 
|-----------| 
231. | . | 
232. | -.188549 | 
233. | . | 
235. | .1628704 | 
241. | . | 
|-----------| 
242. | . | 
244. | . | 
245. | . | 
247. | . | 
248. | . | 
+-----------+ 



























The outliers and influential points seem to be 1003, 1167, 1116 and 1272. These are 
positions/subjects 202, 209, 219 and 240 respectively. There are also two other 




| MumCD4~t lev2 cooksd2 h2 dfMumCD~t | 
|-------------------------------------------------------| 
1. | 413 .0060364 . .0060364 . | 
2. | 634 .0098753 .0098374 .0098753 -.0894529 | 
3. | . . . . . | 
4. | 233 .0113565 .0045886 .0113565 -.066471 | 
5. | 329 .0075754 .0074421 .0075754 -.0578411 | 
|-------------------------------------------------------| 
6. | 255 .0102995 . .0102995 . | 
7. | 391 .0062799 . .0062799 . | 
8. | 18 .0276494 .0063467 .0276494 -.0997994 | 
9. | 685 .0123846 .0003408 .0123846 -.0188645 | 
10. | 331 .0075196 .0081672 .0075196 -.0598439 | 
|-------------------------------------------------------| 
11. | 627 .0095784 .0068184 .0095784 -.0726292 | 
12. | 565 .0074494 .0153183 .0074494 -.0810295 | 
13. | 306 .0082848 .0000393 .0082848 .0047621 | 
14. | 359 .0068362 . .0068362 . | 
15. | 176 .0146221 .0032511 .0146221 -.0622368 | 
|-------------------------------------------------------| 
16. | 446 .0058836 .0040208 .0058836 -.0013141 | 
17. | 289 .0088888 .002452 .0088888 .0406711 | 
18. | 932 .0331509 .005975 .0331509 -.0989517 | 
19. | 341 .0072545 .0023833 .0072545 .029995 | 
20. | 789 .0193879 .0016229 .0193879 .047431 | 
|-------------------------------------------------------| 
21. | 449 .0058824 .0102953 .0058824 .0001821 | 
22. | 312 .0080878 .01323 .0080878 -.0855204 | 
23. | 395 .0062272 .0100875 .0062272 .0336483 | 
24. | 271 .0096019 .0048671 .0096019 -.0614075 | 
25. | 332 .007492 .0037984 .007492 .0404011 | 
|-------------------------------------------------------| 
26. | 101 .0200775 .005048 .0200775 .0843592 | 
91. | 727 .0149081 .0177508 .0149081 -.1472014 | 
 
28. | 174 .0147505 6.31e-06 .0147505 -.0027471 | 
29. | 341 .0072545 .003764 .0072545 .0377373 | 
30. | 531 .0066638 .0028288 .0066638 .0257455 | 
|-------------------------------------------------------| 
31. | 685 .0123846 .0001586 .0123846 -.0128663 | 
32. | 442 .0058886 . .0058886 . | 
33. | 628 .0096201 .0020879 .0096201 -.0402106 | 
34. | 256 .0102542 .0014646 .0102542 -.0352629 | 
35. | 333 .0074647 . .0074647 . | 
|-------------------------------------------------------| 
36. | 353 .0069672 .0000399 .0069672 -.0035141 | 
37. | 460 .0058958 .0012618 .0058958 .0023946 | 
38. | 224 .0118216 .0147933 .0118216 .1224611 | 
39. | 242 .0109104 . .0109104 . | 
40. | 431 .0059215 . .0059215 . | 
|-------------------------------------------------------| 
41. | 205 .0128656 . .0128656 . | 
42. | 441 .0058904 .0083456 .0058904 -.0047955 | 
43. | 149 .0164344 .0069527 .0164344 .094442 | 
44. | 460 .0058958 .0017349 .0058958 .0028092 | 
45. | 568 .0075317 .0006406 .0075317 .0167088 | 
|-------------------------------------------------------| 
46. | 433 .0059134 .0009819 .0059134 .0032034 | 
47. | 235 .0112557 4.11e-06 .0112557 .0019761 | 
48. | 242 .0109104 . .0109104 . | 
49. | 167 .0152072 . .0152072 . | 
50. | 290 .0088514 .0053585 .0088514 .0599927 | 
|-------------------------------------------------------| 
51. | 587 .0081019 .001317 .0081019 .0268082 | 
52. | 512 .0063427 .0100521 .0063427 .0384457 | 
53. | 617 .0091742 .0108194 .0091742 -.0884702 | 
54. | 324 .0077191 .0011318 .0077191 -.0231593 | 
55. | 488 .0060578 .0028539 .0060578 .0128541 | 
|-------------------------------------------------------| 
56. | 764 .0174733 .0036528 .0174733 -.0694918 | 
57. | . . . . . | 
58. | 189 .0138104 .0046686 .0138104 .0731402 | 
59. | . . . . . | 
60. | 443 .005887 .0016996 .005887 -.001631 | 
|-------------------------------------------------------| 
61. | 263 .0099432 . .0099432 . | 
62. | 463 .0059044 .0003082 .0059044 .0015123 | 
63. | 606 .0087565 .0002035 .0087565 -.0115246 | 
64. | 147 .0165754 .0200559 .0165754 -.1615313 | 
65. | 213 .0124157 .0152682 .0124157 .1273087 | 
|-------------------------------------------------------| 
66. | 255 .0102995 . .0102995 . | 
67. | 335 .0074107 .0000506 .0074107 -.0045566 | 
68. | 238 .0111063 .0018798 .0111063 -.041969 | 
69. | 248 .0106235 .0011275 .0106235 -.0316486 | 
70. | 680 .0121116 .0203589 .0121116 -.14573 | 
|-------------------------------------------------------| 
71. | 616 .009135 . .009135 . | 
72. | 355 .0069226 7.21e-06 .0069226 -.001468 | 
73. | 297 .0085961 .0074633 .0085961 .0687951 | 
74. | 306 .0082848 . .0082848 . | 
75. | 262 .0099869 .0105935 .0099869 .0936245 | 
|-------------------------------------------------------| 
76. | 224 .0118216 . .0118216 . | 
77. | 564 .0074224 .0012414 .0074224 .022652 | 
78. | 308 .0082182 .0092366 .0082182 -.0727296 | 
79. | 479 .0059857 .0030263 .0059857 .0102228 | 
80. | 52 .0243527 .0520278 .0243527 -.283633 | 
|-------------------------------------------------------| 
81. | 523 .0065183 .0030821 .0065183 -.0245189 | 
82. | 405 .0061118 .0047738 .0061118 .0189649 | 
83. | 607 .0087933 .0191422 .0087933 -.1137123 | 
84. | 341 .0072545 . .0072545 . | 
85. | 599 .0085055 .0010088 .0085055 -.0248882 | 
|-------------------------------------------------------| 
86. | 535 .0067422 .0002073 .0067422 .0072502 | 
87. | 359 .0068362 .0037123 .0068362 .0321936 | 
88. | 518 .006435 .0003305 .006435 .0075138 | 
89. | 276 .0093962 .0002067 .0093962 -.0123976 | 
90. | 498 .0061601 . .0061601 . | 
|-------------------------------------------------------| 
 
92. | 480 .0059928 . .0059928 . | 
93. | 501 .0061954 .0011956 .0061954 .0109711 | 
94. | 409 .0060722 .006498 .0060722 .020228 | 
95. | 424 .0059572 . .0059572 . | 
|-------------------------------------------------------| 
96. | 355 .0069226 .0008651 .0069226 -.0160882 | 
97. | 196 .0133897 . .0133897 . | 
98. | 572 .0076447 .0012997 .0076447 -.0244313 | 
99. | 424 .0059572 .0000127 .0059572 -.0005635 | 
100. | 278 .0093156 .0077921 .0093156 .0759354 | 
|-------------------------------------------------------| 
101. | 874 .0269918 . .0269918 . | 
102. | 527 .0065892 .0018337 .0065892 -.0198079 | 
103. | 427 .0059405 . .0059405 . | 
104. | 781 .0187593 .008374 .0187593 .107181 | 
105. | 321 .0078081 .0003079 .0078081 .0122907 | 
|-------------------------------------------------------| 
106. | 621 .009333 .0013641 .009333 -.0316923 | 
107. | . . . . . | 
108. | 629 .0096621 .0003305 .0096621 .0160353 | 
109. | 307 .0082514 .0073043 .0082514 .0649103 | 
110. | 314 .0080241 .0064726 .0080241 -.0588871 | 
|-------------------------------------------------------| 
111. | . . . . . | 
112. | 530 .0066448 .001303 .0066448 .0172605 | 
113. | 439 .0058947 .0096615 .0058947 -.006412 | 
114. | 175 .0146862 . .0146862 . | 
115. | 451 .0058827 .0018775 .0058827 .0004689 | 
|-------------------------------------------------------| 
116. | 254 .0103451 .0015598 .0103451 .0366077 | 
117. | 231 .0114582 3.63e-06 .0114582 -.0018742 | 
118. | 691 .0127198 .0022067 .0127198 -.0486114 | 
119. | 503 .00622 .0022304 .00622 .0155487 | 
120. | . . . . . | 
|-------------------------------------------------------| 
121. | 442 .0058886 .0003486 .0058886 -.0008549 | 
122. | 474 .0059539 .0091558 .0059539 .0149211 | 
123. | 451 .0058827 .000081 .0058827 -.0000972 | 
124. | 800 .0202767 .0007808 .0202767 -.0332045 | 
125. | 476 .0059659 .0000728 .0059659 .0014233 | 
|-------------------------------------------------------| 
126. | 653 .010739 .0081134 .010739 -.085792 | 
127. | 117 .0188032 .0195422 .0188032 -.1643942 | 
128. | 450 .0058824 .0039701 .0058824 -.0002855 | 
129. | 480 .0059928 .0035428 .0059928 -.0114322 | 
130. | 237 .0111559 .0025425 .0111559 .0489478 | 
|-------------------------------------------------------| 
131. | 418 .0059969 .0001259 .0059969 -.0021863 | 
132. | 507 .0062722 .0037818 .0062722 .021695 | 
133. | 837 .023474 .0059631 .023474 .0943963 | 
134. | 597 .0084359 .0000133 .0084359 .0028318 | 
135. | 253 .0103909 .0015068 .0103909 -.0360835 | 
|-------------------------------------------------------| 
136. | 608 .0088303 .0013267 .0088303 -.0297008 | 
137. | 595 .0083672 .005525 .0083672 -.0573382 | 
138. | 694 .0128906 . .0128906 . | 
139. | . . . . . | 
140. | 526 .0065711 .0011773 .0065711 .0156799 | 
|-------------------------------------------------------| 
141. | 557 .0072402 .0009201 .0072402 .0185362 | 
142. | 727 .0149081 .0156048 .0149081 .1378987 | 
143. | 308 .0082182 .0065803 .0082182 -.061269 | 
144. | 315 .0079925 .001057 .0079925 .0235732 | 
145. | . . . . . | 
|-------------------------------------------------------| 
146. | 845 .0242075 .0274933 .0242075 .2047692 | 
147. | . . . . . | 
148. | 208 .0126952 .004048 .0126952 -.0658413 | 
149. | . . . . . | 
150. | 261 .0100309 .0000375 .0100309 -.0055497 | 
|-------------------------------------------------------| 
151. | 195 .0134491 .0160697 .0134491 .1350202 | 
152. | 195 .0134491 .0160697 .0134491 .1350202 | 
153. | 130 .017812 . .017812 . | 
154. | . . . . . | 
155. | 865 .0261066 . .0261066 . | 
|-------------------------------------------------------| 
 
156. | 513 .0063575 .0107901 .0063575 .0404474 | 
157. | . . . . . | 
158. | . . . . . | 
159. | 452 .0058832 .0060832 .0058832 .0013412 | 
160. | 200 .0131544 . .0131544 . | 
|-------------------------------------------------------| 
161. | 862 .0258158 .0019814 .0258158 -.0551761 | 
162. | 89 .0210725 .0004953 .0210725 .0266463 | 
163. | . . . . . | 
164. | . . . . . | 
165. | 852 .0248615 . .0248615 . | 
|-------------------------------------------------------| 
166. | 590 .0081996 .0018496 .0081996 -.0322794 | 
167. | 218 .0121422 .000078 .0121422 .008942 | 
168. | 380 .0064441 . .0064441 . | 
169. | 451 .0058827 .0039794 .0058827 -.0006842 | 
170. | . . . . . | 
|-------------------------------------------------------| 
171. | 380 .0064441 . .0064441 . | 
172. | 208 .0126952 .0000902 .0126952 -.0098083 | 
173. | . . . . . | 
174. | 276 .0093962 .00017 .0093962 .0112439 | 
175. | . . . . . | 
|-------------------------------------------------------| 
176. | 507 .0062722 . .0062722 . | 
177. | 471 .0059375 .0000114 .0059375 .0004592 | 
178. | 282 .0091571 .0001798 .0091571 .0113076 | 
179. | 325 .0076899 .0013608 .0076899 -.0252441 | 
180. | 508 .0062858 .0068814 .0062858 .0298273 | 
|-------------------------------------------------------| 
181. | 666 .0113786 .006873 .0113786 -.0815322 | 
182. | 618 .0092135 .0088913 .0092135 -.0804031 | 
183. | . . . . . | 
184. | 221 .0119808 .0076861 .0119808 -.0885284 | 
185. | 527 .0065892 . .0065892 . | 
|-------------------------------------------------------| 
186. | 883 .0278959 . .0278959 . | 
187. | 526 .0065711 .0018221 .0065711 -.0195177 | 
188. | 491 .006086 .0056607 .006086 -.019514 | 
189. | . . . . . | 
190. | 511 .0063281 .0001488 .0063281 .0045648 | 
|-------------------------------------------------------| 
191. | 720 .0144588 .0006554 .0144588 .0278079 | 
192. | 710 .0138369 .0008106 .0138369 -.0304488 | 
193. | 170 .0150101 .0172225 .0150101 .1452773 | 
194. | 354 .0069448 .0006945 .0069448 -.0145424 | 
195. | . . . . . | 
|-------------------------------------------------------| 
196. | 333 .0074647 .0049871 .0074647 .0460266 | 
197. | 417 .0060043 . .0060043 . | 
198. | 242 .0109104 .009421 .0109104 -.0933824 | 
199. | 343 .0072043 .0117343 .0072043 -.0660652 | 
200. | 320 .0078383 .0034407 .0078383 -.0414224 | 
|-------------------------------------------------------| 
201. | 339 .0073056 .0025171 .0073056 -.0312876 | 
202. | 1003 .0417624 .0712725 .0417624 -.3523567 | 
203. | 264 .0098997 .0131868 .0098997 .1039645 | 
204. | 640 .0101389 .0054703 .0101389 .0677865 | 
205. | 598 .0084706 . .0084706 . | 
|-------------------------------------------------------| 
206. | 195 .0134491 . .0134491 . | 
207. | 346 .0071307 . .0071307 . | 
208. | 35 .0259672 .0033423 .0259672 .0717438 | 
209. | 1167 .0661637 .0371318 .0661637 .260155 | 
210. | 362 .0067739 7.78e-06 .0067739 .0014267 | 
|-------------------------------------------------------| 
211. | 174 .0147505 . .0147505 . | 
212. | 607 .0087933 .0094021 .0087933 .0791646 | 
213. | . . . . . | 
214. | 832 .0230232 .008173 .0230232 .110215 | 
215. | 534 .0067222 .0078325 .0067222 .0444157 | 
|-------------------------------------------------------| 
216. | 192 .0136287 .0034434 .0136287 .0624712 | 
217. | 622 .0093734 . .0093734 . | 
218. | 622 .0093734 . .0093734 . | 
219. | 1116 .0579011 .0086098 .0579011 .1241121 | 
220. | . . . . . | 
 
|-------------------------------------------------------| 
221. | 674 .0117918 .000511 .0117918 .022569 | 
222. | 306 .0082848 .0030536 .0082848 .0420493 | 
223. | 644 .0103193 .0000949 .0103193 .0090081 | 
224. | . . . . . | 
225. | . . . . . | 
|-------------------------------------------------------| 
226. | 396 .0062146 . .0062146 . | 
227. | . . . . . | 
228. | . . . . . | 
229. | 702 .0133563 .0018437 .0133563 .0453256 | 
230. | . . . . . | 
|-------------------------------------------------------| 
231. | . . . . . | 
232. | 166 .0152734 .0284476 .0152734 -.188549 | 
233. | . . . . . | 
234. | 872 .0267934 .0005188 .0267934 -.0283747 | 
235. | 975 .0382254 .0156954 .0382254 .1628704 | 
|-------------------------------------------------------| 
236. | 44 .025104 .0009387 .025104 .03781 | 
237. | 292 .0087773 .000425 .0087773 .0166978 | 
238. | 392 .0062663 9.54e-06 .0062663 -.0010783 | 
239. | 70 .0227169 .0120633 .0227169 .1337285 | 
240. | 1272 .0850919 .0018495 .0850919 .0585122 | 
|-------------------------------------------------------| 
241. | . . . . . | 
242. | . . . . . | 
243. | 326 .007661 .0007253 .007661 .0183069 | 
244. | . . . . . | 
245. | 545 .0069545 . .0069545 . | 
|-------------------------------------------------------| 
246. | 381 .006428 .0001939 .006428 .0057219 | 
247. | . . . . . | 
248. | . . . . . | 
+-------------------------------------------------------+ 
 
3. Linear regression model 3: Simple model with the dependent variable (Maternal 
QFT IFN-γ) log transformed (natural log) and Maternal CD4 count per 50 cells/mm3 
for more meaningful interpretation. The outliers/influential points were not removed. 
 
 
Source | SS df MS Number of obs = 170 
-------------+------------------------------ F( 1, 168) = 14.85 
Model | 57.2200372 1 57.2200372 Prob > F = 0.0002 
Residual | 647.265007 168 3.8527679 R-squared = 0.0812 
-------------+------------------------------ Adj R-squared = 0.0758 
Total | 704.485044 169 4.16855056 Root MSE = 1.9628 
 
------------------------------------------------------------------------------ 
MumQFTtbag~n | Coef. Std. Err. t P>|t| [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
cd4_50 | .1293844 .0335733 3.85 0.000 .0631045 .1956644 




4. Linear regression model 4: Simple model with the dependent variable (Maternal 
QFT IFN-γ) log transformed (natural log) and Maternal CD4 count per 50 cells/mm3 
for more meaningful interpretation. The outliers/influential points were removed. 
Source | SS df MS Number of obs = 167 
-------------+------------------------------ F( 1, 165) = 20.35 
Model | 75.9457144 1 75.9457144 Prob > F = 0.0000 
Residual | 615.743144 165 3.73177663 R-squared = 0.1098 
-------------+------------------------------ Adj R-squared = 0.1044 
Total | 691.688858 166 4.16680035 Root MSE = 1.9318 
 
------------------------------------------------------------------------------ 
MumQFTtbag~n | Coef. Std. Err. t P>|t| [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
 
modcd4 | .1550828 .0343772 4.51 0.000 .087207 .2229586 










Interpretation of this model: 
 
The F test = 20.35 and is statistically significant at all levels (p<0.0001), hence the 
model explains a significant amount of variation in maternal QFT. R2 = 0.1098 so 
10.98% of the variability in the maternal QFT is explained by the model. The linear 
regression equation is: predicted natural log maternal QFT-γ= -2.359 + 
0.155*maternal CD4 count (cells/mm3/50). 
 
Back transforming the log-transformed maternal QFT-γ: (e0.155 – 1)*100 = (1.16- 
1)*100 = 0.167*100 =16.76% 
 
For every 50 unit (cells/mm3) increase in maternal CD4 count, maternal QFT IFN -γ 
IU/ml will increase by 17% (1.17 times), on average. 
 
APPENDIX A: ADDITIONAL DISSERTATION ANALYSIS 
 
APPENDIX A2: Linear regression of demographic and clinical risk factors associated 
with M.tb infection in HIV exposed infants 
 
1. Full dataset without removal of missing QFT results and the two values over 12 
IU/ml (13.15 and 14.28 IU/ml) 
 
2. Linear regression model 1: Infant IFN-γ (IU/ml) with outliers removed and new 
HHC as this model with only one independent variable was the best model 
xi:regress BabyQFTtbagnil_mod12 i.InfNewHHC 
Source | SS df MS Number of obs = 196 
-------------+------------------------------ F( 1, 194) = 9.98 
Model | 1.30206578 1 1.30206578 Prob > F = 0.0018 
Residual | 25.3140512 194 .1304848 R-squared = 0.0489 
-------------+------------------------------ Adj R-squared = 0.0440 
Total | 26.616117 195 .136492908 Root MSE = .36123 
 
------------------------------------------------------------------------------- 
BabyQ~l_mod12 | Coef. Std. Err. t P>|t| [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
_IInfNewHHC_2 | .3894058 .1232724 3.16 0.002 .1462796 .632532 




2.1 Checking assumptions. 
 
Dependent variable is not normally distributed. 
2.1.1 Checking for normality of residuals 
Shapiro-Wilk W test for normal data 
Variable | Obs W V z Prob>z 
-------------+-------------------------------------------------- 




























3. Linear regression model 2: Log-transformed (natural log) Infant IFN-γ (IU/ml) with 
outliers removed and new HHC 
 
 
3.1 Checking for normality of variables of this model 
Shapiro-Wilk W test for normal data 
Variable | Obs W V z Prob>z 
-------------+-------------------------------------------------- 


























Still not normally distributed 
 


































Source | SS df MS Number of obs = 81 
-------------+------------------------------ F( 1, 79) = 31.85 
Model | 32.1656679 1 32.1656679 Prob > F = 0.0000 
Residual | 79.785432 79 1.00994218 R-squared = 0.2873 
-------------+------------------------------ Adj R-squared = 0.2783 
Total | 111.9511 80 1.39938875 Root MSE = 1.005 
 
------------------------------------------------------------------------------- 
BabyQFTt~2_ln | Coef. Std. Err. t P>|t| [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
_IInfNewHHC_2 | 4.060787 .7195521 5.64 0.000 2.628555 5.49302 
_cons | -3.567506 .1130667 -31.55 0.000 -3.79256 -3.342452 
------------------------------------------------------------------------------- 
 
The linear regression established that a new household TB contact could statistically 
significantly predict the infant QFT IFN- γ value (IU/ml) with the F test (1,79) = 31.85, 
p=0.0000). A new household contact accounted for 28.73% (R2=0.2873) of the 
explained variability in infant QFT IFN- γ value (IU/ml). 
The linear regression equation is: predicted natural log Infant QFT IFN- γ = -3.57 + 
4.06*Infant new HHC. 
Back transforming the dependent variable: (e4.06 -1)*100 = (57.9-1)*100 = 56.9*100 = 
569% OR 57.9 fold 
 
Infants who had a new household contact have QFT IFN- γ values (IU/ml) 58 fold 
higher than those infants without a new household contact, on average This was 
statistically significant at all levels (p<0.0001). 
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Books Bates B. Bargaining for life: A social history of tuberculosis. 1st ed. Philadelphia: University of 
Pennsylvania Press; 1992. 
 
A reference management tool, EndNote, offers a current style file that can assist you with the formatting of your references. If 
you have problems with any reference management program, please contact the source company's technical support. 
# Do not include funding sources in the Acknowledgments or anywhere else in the manuscript file. Funding information 
should only be entered in the financial disclosure section of the submission system. 
# Because all references will be linked electronically as much as possible to the papers they cite, proper formatting of the 
references is crucial. 
 
 
Book chapters Hansen B. New York City epidemics and history for the public. In: Harden VA, Risse GB, editors. AIDS 




e-prints, or arXiv) 
Krick T, Shub DA, Verstraete N, Ferreiro DU, Alonso LG, Shub M, et al. Amino acid metabolism conflicts 
with protein diversity; 1991. Preprint. Available from: arXiv:1403.3301v1. Cited 17 March 2014. 
 
Published media 
(print or online 
newspapers and 
magazine articles) 
Fountain H. For Already Vulnerable Penguins, Study Finds Climate Change Is Another Danger. The New 
York Times. 29 Jan 2014. Available from: http://www.nytimes.com/2014/01/30/science/earth/climate- 
change-taking-toll-on-penguins-study-finds.html Cited 17 March 2014. 
 
New media (blogs, 
web sites, or other 
written works) 
Allen L. Announcing PLOS Blogs. 2010 Sep 1 [cited 17 March 2014]. In: PLOS Blogs [Internet]. San 
Francisco: PLOS 2006 - . [about 2 screens]. Available from: 
http://blogs.plos.org/plos/2010/09/announcing-plos-blogs/. 
 
Masters' theses or 
doctoral 
dissertations 
Wells A. Exploring the development of the independent, electronic, scholarly journal. M.Sc. Thesis, The 





Roberts SB. QPX Genome Browser Feature Tracks; 2013 [cited 2013 Oct 5]. Database: figshare 




or TV shows) 





Authors can submit essential supporting files and multimedia files along with their manuscripts. All 
supporting information will be subject to peer review. All file types can be submitted, but files must be 
smaller than 10 MB in size. 
Authors may use almost any description as the item name for a supporting information file as long as it 
contains an “S” and number. For example, “S1 Appendix” and “S2 Appendix,” “S1 Table” and “S2 
Table,” and so forth. 
Supporting information files are published exactly as provided, and are not copyedited. 
Supporting information captions 
List supporting information captions at the end of the manuscript file. Do not submit captions in a separate 
file. 
The file number and name are required in a caption, and we highly recommend including a one-line title as 













We recommend that you cite supporting information in the manuscript text, but this is not a requirement. If 







Figures and Tables 
 
Figures 
Do not include figures in the main manuscript file. Each figure must be prepared and submitted as an 
individual file. 
Cite figures in ascending numeric order upon first appearance in the manuscript file. 
Example caption 
S1 Text. Title is strongly recommended. Legend is optional. 
 Read the supporting information guidelines for more details about submitting supporting information and multimedia 
files. 
 Read the guidelines for figures. 
 
Figure captions 
Figure captions must be inserted in the text of the manuscript, immediately following the paragraph in 
which the figure is first cited (read order). Do not include captions as part of the figure files themselves or 
submit them in a separate document. 
At a minimum, include the following in your figure captions: 
 
! A figure label with Arabic numerals, and “Figure” abbreviated to “Fig” (e.g. Fig 1, Fig 2, Fig 3, etc). Match the label of your 
figure with the name of the file uploaded at submission (e.g. a figure citation of “Fig 1” must refer to a figure file named 
“Fig1.tif”). 
! A concise, descriptive title 
 







Cite tables in ascending numeric order upon first appearance in the manuscript file. 
Place each table in your manuscript file directly after the paragraph in which it is first cited (read order). Do 
not submit your tables in separate files. 
Tables require a label (e.g., “Table 1”) and brief descriptive title to be placed above the table. Place 








All data and related metadata underlying the findings reported in a submitted manuscript should be 





Repositories may be either subject-specific (where these exist) and accept specific types of structured 
data, or generalist repositories that accept multiple data types. We recommend that authors select 
repositories appropriate to their field. Repositories may be subject-specific (e.g., GenBank for sequences 
and PDB for structures), general, or institutional, as long as DOIs or accession numbers are provided and 
the data are at least as open as CC BY. Authors are encouraged to select repositories that meet accepted 
criteria as trustworthy digital repositories, such as criteria of the Centre for Research Libraries or Data Seal 





To support data sharing and author compliance of the PLOS data policy, we have integrated our 
submission process with a select set of data repositories. The list is neither representative nor exhaustive 
of the suitable repositories available to authors. Current repository integration partners include Dryad and 
FlowRepository. Please contact data@plos.org to make recommendations for further partnerships. 
Instructions for PLOS submissions with data deposited in an integration partner repository: 
 
! Deposit data in the integrated repository of choice. 
! Once deposition is final and complete, the repository will provide you with a dataset DOI (provisional) and private URL for 
reviewers to gain access to the data. 
! Enter the given data DOI into the full Data Availability Statement, which is requested in the Additional Information section of 
the PLOS submission form. Then provide the URL passcode in the Attach Files section. 
 




All appropriate data sets, images, and information should be deposited in an appropriate public repository. 
See our list of recommended repositories. 
Accession numbers (and version numbers, if appropriate) should be provided in the Data Availability 
Statement. Accession numbers or a citation to the DOI should also be provided when the data set is 
mentioned within the manuscript. 
 Read more about figure captions. 
 Read the guidelines for tables. 
 Read our policy on data availability. 
 See our list of recommended repositories. 
 
In some cases authors may not be able to obtain accession numbers of DOIs until the manuscript is 
accepted; in these cases, the authors must provide these numbers at acceptance. In all other cases, these 
numbers must be provided at submission. 
Identifiers 
As much as possible, please provide accession numbers or identifiers for all entities such as genes, 
proteins, mutants, diseases, etc., for which there is an entry in a public database, for example: 
 
! Ensembl 
! Entrez Gene 
! FlyBase 
! InterPro 
! Mouse Genome Database (MGD) 
! Online Mendelian Inheritance in Man (OMIM) 
! PubChem 
 




You can choose to upload a “Striking Image” that we may use to represent your article online in places like 
the journal homepage or in search results. 
The striking image must be derived from a figure or supporting information file from the submission, i.e., a 
cropped portion of an image or the entire image. Striking images should ideally be high resolution, eye- 
catching, single panel images, and should ideally avoid containing added details such as text, scale bars, 
and arrows. 












This information should not be in your manuscript file; you will provide it via our submission system. 
This information will be published with the final manuscript, if accepted, so please make sure that this is 
accurate and as detailed as possible. You should not include this information in your manuscript file, but it 
is important to gather it prior to submission, because your financial disclosure statement cannot be 
changed after initial submission. 
Your statement should include relevant grant numbers and the URL of any funder's web site. Please also 
state whether any individuals employed or contracted by the funders (other than the named authors) played 
any role in: study design, data collection and analysis, decision to publish, or preparation of the manuscript. 








This information should not be in your manuscript file; you will provide it via our submission system. 
All potential competing interests must be declared in full. If the submission is related to any patents, patent 
applications, or products in development or for market, these details, including patent numbers and titles, 






Manuscripts disputing published work 
 
For manuscripts disputing previously published work, it is PLOS ONE policy to invite a signed review by the 
disputed author during the peer review process. This procedure is aimed at ensuring a thorough, 
transparent, and productive review process. 
 Striking images should not contain potentially identifying images of people. Read our policy on identifying information. 
The PLOS licenses and copyright policy also applies to striking images. 
 Read our policy on disclosure of funding sources. 
 Read our policy on competing interests. 
 
If the disputed author chooses to submit a review, it must be returned in a timely fashion and contain a full 
declaration of all competing interests. The Academic Editor will consider any such reviews in light of the 
competing interest. 
Authors submitting manuscripts disputing previous work should explain the relationship between the 
manuscripts in their cover letter, and will be required to confirm that they accept the conditions of this 




Upon submission, authors must confirm that the manuscript, or any related manuscript, is not currently 
under consideration or accepted elsewhere. If related work has been submitted to PLOS ONE or 
elsewhere, authors must include a copy with the submitted article. Reviewers will be asked to comment on 
the overlap between related submissions. 
We strongly discourage the unnecessary division of related work into separate manuscripts, and we will not 
consider manuscripts that are divided into “parts.” Each submission to PLOS ONE must be written as an 
independent unit and should not rely on any work that has not already been accepted for publication. If 
related manuscripts are submitted to PLOS ONE, the authors may be advised to combine them into a 
single manuscript at the editor's discretion. 
PLOS does support authors who wish to share their work early and receive feedback before formal peer 
review. Deposition of manuscripts with preprint servers does not impact consideration of the manuscript at 
any PLOS journal. 
Authors choosing bioRxiv may now concurrently submit directly to select PLOS journals through bioRxiv’s 






Guidelines for Specific Study Types 
 
































Manuscripts should conform to the following reporting guidelines: 
 
! Studies of diagnostic accuracy: STARD 
! Observational studies: STROBE 
! Microarray experiments: MIAME 
! Other types of health-related research: Consult the EQUATOR web site for appropriate reporting guidelines 
 
Methods sections of papers on research using human subjects or samples must include ethics statements 
that specify: 
 
! The name of the approving institutional review board or equivalent committee(s). If approval was not obtained, the 
authors must provide a detailed statement explaining why it was not needed 
! Whether informed consent was written or oral. If informed consent was oral, it must be stated in the manuscript: 
! Why written consent could not be obtained 
! That the Institutional Review Board (IRB) approved use of oral consent 
! How oral consent was documented 
All research involving human participants must have been approved by the authors’ Institutional Review Board (IRB) or by 
equivalent ethics committee(s), and must have been conducted according to the principles expressed in the Declaration of 
Helsinki. Authors should be able to submit, upon request, a statement from the IRB or ethics committee indicating approval of 
the research. We reserve the right to reject work that we believe has not been conducted to a high ethical standard, even 
when formal approval has been obtained. 
Subjects must have been properly instructed and have indicated that they consent to participate by signing the appropriate 
informed consent paperwork. Authors may be asked to submit a blank, sample copy of a subject consent form. If consent 
was verbal instead of written, or if consent could not be obtained, the authors must explain the reason in the manuscript, and 
the use of verbal consent or the lack of consent must have been approved by the IRB or ethics committee. 
All efforts should be made to protect patient privacy and anonymity. Identifying information, including photos, should not be 
included in the manuscript unless the information is crucial and the individual has provided written consent by completing the 
Consent Form for Publication in a PLOS Journal (PDF). Download additional translations of the form from the Downloads 
and Translations page. More information about patient privacy, anonymity, and informed consent can be found in the 
International Committee of Medical Journal Editors (ICMJE) Privacy and Confidentiality guidelines. 
 Read our policies on related manuscripts and preprint servers. 
 
For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, sex/gender, 
sexual orientation, or other socially constructed groupings, authors should: 
 
! Explicitly describe their methods of categorizing human populations 
! Define categories in as much detail as the study protocol allows 
! Justify their choices of definitions and categories, including for example whether any rules of human categorization were 
required by their funding agency 
! Explain whether (and if so, how) they controlled for confounding variables such as socioeconomic status, nutrition, 
environmental exposures, or similar factors in their analysis 
 
In addition, outmoded terms and potentially stigmatizing labels should be changed to more current, 
acceptable terminology. Examples: “Caucasian” should be changed to “white” or “of [Western] European 
descent” (as appropriate); “cancer victims” should be changed to “patients with cancer.” 
For papers that include identifying, or potentially identifying, information, authors must download 
the Consent Form for Publication in a PLOS Journal, which the individual, parent, or guardian must sign 
once they have read the paper and been informed about the terms of PLOS open-access license. The 
signed consent form should not be submitted with the manuscript, but authors should securely file it in the 
individual's case notes and the methods section of the manuscript should explicitly state that consent 
authorization for publication is on file, using wording like: 
The individual in this manuscript has given written informed consent (as outlined in PLOS consent 
form) to publish these case details. 
For more information about PLOS ONE policies regarding human subjects research, see the Publication 




Clinical trials are subject to all policies regarding human research. PLOS ONE follows the World Health 




All clinical trials must be registered in one of the publicly-accessible registries approved by 
the WHO or ICMJE (International Committee of Medical Journal Editors). Authors must provide the trial 
registration number. Prior disclosure of results on a clinical trial registry site will not affect consideration for 
publication. We reserve the right to inform authors' institutions or ethics committees, and to reject the 
manuscript, if we become aware of unregistered trials. 
PLOS ONE supports prospective trial registration (i.e. before participant recruitment has begun) as 
recommended by the ICMJE's clinical trial registration policy. Where trials were not publicly registered 
before participant recruitment began, authors must: 
 
! Register all related clinical trials and confirm they have done so in the Methods section 
! Explain in the Methods the reason for failing to register before participant recruitment 
 
Clinical trials must be reported according to the relevant reporting guidelines, i.e. CONSORT for 
randomized controlled trials, TREND for non-randomized trials, and other specialized guidelines as 
appropriate. The intervention should be described according to the requirements of the TIDieR checklist 
and guide. Submissions must also include the study protocol as supporting information, which will be 
published with the manuscript if accepted. 
Authors of manuscripts describing the results of clinical trials must adhere to the CONSORT reporting 
guidelines appropriate to their trial design, available on the CONSORT Statement web site. Before the 
paper can enter peer review, authors must: 
 
! Provide the registry name and number in the methods section of the manuscript  
! Provide a copy of the trial protocol as approved by the ethics committee and a completed CONSORT checklist as supporting 
information (which will be published alongside the paper, if accepted). This should be named S1 CONSORT Checklist. 
! Include the CONSORT flow diagram as the manuscript's “Fig 1” 
 
Any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss 
informed consent in their paper, and we reserve the right to ask for a copy of the patient consent form. 
The methods section must include the name of the registry, the registry number, and the URL of your trial in 
the registry database for each location in which the trial is registered. 
 
Animal research 
A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more 
health-related interventions to evaluate the effects on health outcomes [...] Interventions include but are not restricted to 
drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, 












Manuscripts reporting animal research must state in the Methods section: 
 
! The full name of the relevant ethics committee that approved the work, and the associated permit number(s).  
! Where ethical approval is not required, the manuscript should include a clear statement of this and the reason why. Provide 
any relevant regulations under which the study is exempt from the requirement for approval. 


















Authors should always state the organism(s) studied in the Abstract. Where the study may be confused as 
pertaining to clinical research, authors should also state the animal model in the title. 
To maximize reproducibility and potential for re-use of data, we encourage authors to follow the Animal 
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for all submissions describing laboratory- 
based animal research and to upload a completed ARRIVE Guidelines Checklist to be published as 
supporting information. 
Non-human primates 
Manuscripts describing research involving non-human primates must report details of husbandry and 
animal welfare in accordance with the recommendations of the Weatherall report, The use of non-human 
primates in research (PDF), including: 
 
! Information about housing, feeding, and environmental enrichment. 
! Steps taken to minimize suffering, including use of anesthesia and method of sacrifice, if appropriate. 
 
Random source animals 
Manuscripts describing studies that use random source (e.g. Class B dealer-sourced in the USA), shelter, 
or stray animals will be subject to additional scrutiny and may be rejected if sufficient ethical and scientific 
justification for the study design is lacking. 
Unacceptable euthanasia methods and anesthetic agents 
Manuscripts reporting use of a euthanasia method(s) classified as unacceptable by the American 
Veterinary Medical Association or use of an anesthesia method(s) that is widely prohibited (e.g., chloral 
hydrate, ether, chloroform) must include at the time of initial submission, scientific justification for use in the 
specific study design, as well as confirmation of approval for specific use from their animal research ethics 
committee. These manuscripts may be subject to additional ethics considerations prior to publication. 
Humane endpoints 
Manuscripts reporting studies in which death of a regulated animal (vertebrate, cephalopod) is a likely 
outcome or a planned experimental endpoint, must comprehensively report details of study design, 
rationale for the approach, and methodology, including consideration of humane endpoints. This applies to 
research that involves, for instance, assessment of survival, toxicity, longevity, terminal disease, or high 

























Full details of humane endpoints use must be reported for a study to be reproducible and for the results to 
be accurately interpreted. 
 
All research involving vertebrates or cephalopods must have approval from the authors' Institutional Animal Care and Use 
Committee (IACUC) or equivalent ethics committee(s), and must have been conducted according to applicable national and 
international guidelines. Approval must be received prior to beginning research. 
Example ethics statement 
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal 
Experiments of the University of Minnesota (Protocol Number: 27-2956). All surgery was performed under sodium 
pentobarbital anesthesia, and all efforts were made to minimize suffering. 
Definition of a humane endpoint 
A humane endpoint is a predefined experimental endpoint at which animals are euthanized when they display early markers 
associated with death or poor prognosis of quality of life, or specific signs of severe suffering or distress. Humane endpoints 
are used as an alternative to allowing such conditions to continue or progress to death following the experimental intervention 
(“death as an endpoint”), or only euthanizing animals at the end of an experiment. Before a study begins, researchers define 
the practical observations or measurements that will be used during the study to recognize a humane endpoint, based on 
anticipated clinical, physiological, and behavioral signs. Please see the NC3Rs guidelines for more information. Additional 
discussion of humane endpoints can be found in this article: Nuno H. Franco, Margarida Correia-Neves, I. Anna S. Olsson 
(2012) How “Humane” Is Your Endpoint? — Refining the Science-Driven Approach for Termination of Animal Studies of 
Chronic Infection. PLoS Pathog 8(1): e1002399 doi.org/10.1371/journal.ppat.1002399. 
 
For studies in which death of an animal is an outcome or a planned experimental endpoint, authors should 
include the following information in the Methods section of the manuscript: 
 
! The specific criteria (i.e. humane endpoints) used to determine when animals should be euthanized.  
! The duration of the experiment. 
! The numbers of animals used, euthanized, and found dead (if any); the cause of death for all animals. 
! How frequently animal health and behavior were monitored. 
! All animal welfare considerations taken, including efforts to minimize suffering and distress, use of analgesics or 
anaesthetics, or special housing conditions. 
 
If humane endpoints were not used, the manuscript should report: 
 
! A scientific justification for the study design, including the reasons why humane endpoints could not be used, and discussion 
of alternatives that were considered. 




Observational and field studies 
 
Methods sections for submissions reporting on any type of field study must include ethics statements that 
specify: 
 
! Permits and approvals obtained for the work, including the full name of the authority that approved the study; if none were 
required, authors should explain why 
! Whether the land accessed is privately owned or protected 
! Whether any protected species were sampled 
! Full details of animal husbandry, experimentation, and care/welfare, where relevant 
 
 
Paleontology and archaeology research 
 
Manuscripts reporting paleontology and archaeology research must include descriptions of methods and 
specimens in sufficient detail to allow the work to be reproduced. Data sets supporting statistical and 
phylogenetic analyses should be provided, preferably in a format that allows easy re-use. Read the policy. 
Specimen numbers and complete repository information, including museum name and geographic location, 
are required for publication. Locality information should be provided in the manuscript as legally allowable, 
or a statement should be included giving details of the availability of such information to qualified 
researchers. 
If permits were required for any aspect of the work, details should be given of all permits that were 



























Systematic reviews and meta-analyses 
 
A systematic review paper, as defined by The Cochrane Collaboration, is a review of a clearly formulated 
question that uses explicit, systematic methods to identify, select, and critically appraise relevant research, 
and to collect and analyze data from the studies that are included in the review. These reviews differ 
substantially from narrative-based reviews or synthesis articles. Statistical methods (meta-analysis) may or 
may not be used to analyze and summarize the results of the included studies. 
Reports of systematic reviews and meta-analyses must include a completed PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) checklist and flow diagram to accompany the main text. 
Blank templates are available here: 
 
! Checklist: PDF or Word document 
All necessary permits were obtained for the described study, which complied with all relevant regulations. 
No permits were required for the described study, which complied with all relevant regulations. 
 





! Flow diagram: PDF or Word document 
 
Authors must also state in their “Methods” section whether a protocol exists for their systematic review, and 
if so, provide a copy of the protocol as supporting information and provide the registry number in the 
abstract. 
If your article is a systematic review or a meta-analysis you should: 
 
! State this in your cover letter 
! Select “Research Article” as your article type when submitting 
! Include the PRISMA flow diagram as Fig 1 (required where applicable) 
! Include the PRISMA checklist as supporting information 
 
 
Meta-analysis of genetic association studies 
 
Manuscripts reporting a meta-analysis of genetic association studies must report results of value to the field 
and should be reported according to the guidelines presented in Systematic Reviews of Genetic 
Association Studies by Sagoo et al. 
On submission, authors will be asked to justify the rationale for the meta-analysis and how it contributes to 
the base of scientific knowledge in the light of previously published results. Authors will also be asked to 
complete a checklist (DOCX) outlining information about the justification for the study and the methodology 
employed. Meta-analyses that replicate published studies will be rejected if the authors do not provide 
adequate justification. 
 
Personal data from third-party sources 
 
For all studies using personal data from internet-based and other third-party sources (e.g., social media, blogs, 
other internet sources, mobile phone companies), data must be collected and used according to company/website 
Terms and Conditions, with appropriate permissions. All data sources must be acknowledged clearly in the 





In the Ethics Statement, authors should declare any potential risks to individuals or individual privacy, or 
affirm that in their assessment, the study posed no such risks. In addition, the following Ethics and Data 
Protection requirements must be met. 
For interventional studies, which impact participants’ experiences or data, the study design must have been 
prospectively approved by an Ethics Committee, and informed consent is required. The Ethics Committee may 
waive the requirement for approval and/or consent. 
For observational studies in which personal experiences and accounts are not manipulated, consultation with an 
Ethics or Data Protection Committee is recommended. Additional requirements apply in the following 
circumstances: 
 
! If information used could threaten personal privacy or damage the reputation of individuals whose data are used, an Ethics 
Committee should be consulted and informed consent obtained or specifically addressed. 
! If authors accessed any personal identifying information, an Ethics or Data Protection Committee should oversee data 




















Authors reporting research using cell lines should state when and where they obtained the cells, giving the 
date and the name of the researcher, cell line repository, or commercial source (company) who provided 
the cells, as appropriate. 
Authors must also include the following information for each cell line: 
For de novo (new) cell lines, including those given to the researchers as a gift, authors must follow our 
 
Note that Terms of Use contracts do not qualify as informed consent, even if they address the use of personal data for research. 
 Read our policy on data availability. 
 See our reporting guidelines for human subjects research. 
 
policies for human subjects research or animal research, as appropriate. The ethics statement must 
include: 
 
! Details of institutional review board or ethics committee approval; AND 
! For human cells, confirmation of written informed consent from the donor, guardian, or next of kin 
 
For established cell lines, the Methods section should include: 
 
! A reference to the published article that first described the cell line; AND/OR 
! The cell line repository or company the cell line was obtained from, the catalogue number, and whether the cell line was 
obtained directly from the repository/company or from another laboratory 
 
Authors should check established cell lines using the ICLAC Database of Cross-contaminated or 
Misidentified Cell Lines to confirm they are not misidentified or contaminated. Cell line authentication is 
recommended – e.g., by karyotyping, isozyme analysis, or short tandem repeats (STR) analysis – and may 
be required during peer review or after publication. 
 
Blots and gels 
 
Manuscripts reporting results from blots (including Western blots) and electrophoretic gels should follow 
these guidelines: 
 
! In accordance with our policy on image manipulation, the image should not be adjusted in any way that could affect the 
scientific information displayed, e.g. by modifying the background or contrast. 
! All blots and gels that support results reported in the manuscript should be provided.  
! Original uncropped and unadjusted blots and gels, including molecular size markers, should be provided in either the figures 
or the supplementary files. 
! Lanes should not be overcropped around the bands; the image should show most or all of the blot or gel. Any non-specific 
bands should be shown and an explanation of their nature should be given. 
! The image should include all relevant controls, and controls should be run on the same blot or gel as the samples. 
! A figure panel should not include composite images of bands originating from different blots or gels. If the figure shows non- 
adjacent bands from the same blot or gel, this should be clearly denoted by vertical black lines and the figure legend should 





Manuscripts reporting experiments using antibodies should include the following information: 
 
! The name of each antibody, a description of whether it is monoclonal or polyclonal, and the host species.  
! The commercial supplier or source laboratory. 
! The catalogue or clone number and, if known, the batch number. 
! The antigen(s) used to raise the antibody. 
! For established antibodies, a stable public identifier from the Antibody Registry. 
 
The manuscript should also report the following experimental details: 
 
! The final antibody concentration or dilution. 
! A reference to the validation study if the antibody was previously validated. If not, provide details of how the authors validated 











Small and macromolecule crystal data 
 
Manuscripts reporting new and unpublished three-dimensional structures must include sufficient supporting 
data and detailed descriptions of the methodologies used to allow the reproduction and validation of the 
structures. All novel structures must have been deposited in a community endorsed database prior to 
submission (please see our list of recommended repositories). 
Small molecule single crystal data 
Authors reporting X-Ray crystallographic structures of small organic, metal-organic, and inorganic 
molecules must deposit their data with the Cambridge Crystallographic Data Centre (CCDC), the Inorganic 
Crystal Structure Database (ICSD), or similar community databases providing a recognized validation 
functionality. Authors are also required to include the relevant structure reference numbers within the main 
text (e.g. the CCDC ID number), as well as the crystallographic information files (.cif format) as 
Supplementary Information, along with the checkCIF validation reports that can be obtained via the 
International Union of Crystallography (IUCr). 
Macromolecular structures 
Authors reporting novel macromolecular structures must have deposited their data prior to submission with 
the Worldwide Protein Data Bank (wwPDB), the Biological Magnetic Resonance Data Bank (BMRB), the 
Electron Microscopy Data Bank (EMDB), or other community databases providing a recognized validation 
 
We encourage authors to consider adding information on new validations to a publicly available database such as 
Antibodypedia or CiteAb. 
 
functionality. Authors must include the structure reference numbers within the main text and submit as 
Supplementary Information the official validation reports from these databases. 
 
Methods, software, databases, and tools 
 
PLOS ONE will consider submissions that present new methods, software, or databases as the primary 











































Manuscripts whose primary purpose is the description of new software must provide full details of the 
algorithms designed. Describe any dependencies on commercial products or operating system. Include 
details of the supplied test data and explain how to install and run the software. A brief description of 
enhancements made in the major releases of the software may also be given. Authors should provide a 
direct link to the deposited software from within the paper. 
Database submissions 
For descriptions of databases, provide details about how the data were curated, as well as plans for long- 
term database maintenance, growth, and stability. Authors should provide a direct link to the database 






New taxon names 
 
Zoological names 
When publishing papers that describe a new zoological taxon name, PLOS aims to comply with the 
requirements of the International Commission on Zoological Nomenclature (ICZN). Effective 1 January 
2012, the ICZN considers an online-only publication to be legitimate if it meets the criteria of archiving and 
is registered in ZooBank, the ICZN's official registry. 
For proper registration of a new zoological taxon, we require two specific statements to be included in your 
manuscript. 
In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science Identifier 




You will need to contact Zoobank to obtain a GUID (LSID). Please do this as early as possible to avoid 
delay of publication upon acceptance of your manuscript. It is your responsibility to provide us with this 
information so we can include it in the final published paper. 
Please also insert the following text into the Methods section, in a sub-section to be called “Nomenclatural 
Acts”: 
Anochetus boltoni Fisher sp. nov. urn:lsid:zoobank.org:act:B6C072CF-1CA6-40C7-8396-534E91EF7FBB 
Utility 
The tool must be of use to the community and must present a proven advantage over existing alternatives, where applicable. 
Recapitulation of existing methods, software, or databases is not useful and will not be considered for publication. Combining 
data and/or functionalities from other sources may be acceptable, but simpler instances (i.e. presenting a subset of an 
already existing database) may not be considered. For software, databases, and online tools, the long-term utility should also 
be discussed, as relevant. This discussion may include maintenance, the potential for future growth, and the stability of the 
hosting, as applicable. 
Validation 
Submissions presenting methods, software, databases, or tools must demonstrate that the new tool achieves its intended 
purpose. If similar options already exist, the submitted manuscript must demonstrate that the new tool is an improvement 
over existing options in some way. This requirement may be met by including a proof-of-principle experiment or analysis; if 
this is not possible, a discussion of the possible applications and some preliminary analysis may be sufficient. 
Availability 
If the manuscript’s primary purpose is the description of new software or a new software package, this software must be 
open source, deposited in an appropriate archive, and conform to the Open Source Definition. If the manuscript mainly 
describes a databse, this database must be open-access and hosted somewhere publicly accessible, and any software used 
to generate a database should also be open source. If relevant, databases should be open for appropriate deposition of 
additional data. Dependency on commercial software such as Mathematica and MATLAB does not preclude a paper from 
consideration, although complete open source solutions are preferred. In these cases, authors should provide a direct link to 
the deposited software or the database hosting site from within the paper. 
 
The electronic edition of this article conforms to the requirements of the amended International Code of Zoological 















All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those of your co- 
authors, has its own repository, we recommend that you also deposit the published online article there and 
include the name in your article. 
Botanical names 
When publishing papers that describe a new botanical taxon, PLOS aims to comply with the requirements 
of the International Code of Nomenclature for algae, fungi, and plants (ICN). The following guidelines for 
publication in an online-only journal have been agreed such that any scientific botanical name published by 
us is considered effectively published under the rules of the Code. Please note that these guidelines differ 
from those for zoological nomenclature, and apply only to seed plants, ferns, and lycophytes. 
Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or English. This 
does not affect the requirements for scientific names, which are still to be Latin. 
Also effective January 2012, the electronic PDF represents a published work according to the ICN for 
algae, fungi, and plants. Therefore the new names contained in the electronic publication of PLOS article 
are effectively published under that Code from the electronic edition alone, so there is no longer any need 
to provide printed copies. 
Additional information describing recent changes to the Code can be found here. 
For proper registration of the new taxon, we require two specific statements to be included in your 
manuscript. 
In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science Identifier 




Journal staff will contact IPNI to obtain the GUID (LSID) after your manuscript is accepted for publication, 
and this information will then be added to the manuscript during the production phase 























All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those of your co- 
authors, has its own repository, we recommend that you also deposit the published online article there and 
include the name in your article. 
Fungal names 
When publishing papers that describe a new botanical taxon, PLOS aims to comply with the requirements 
of the International Code of Nomenclature for algae, fungi, and plants (ICN). The following guidelines for 
publication in an online-only journal have been agreed such that any scientific botanical name published by 
us is considered effectively published under the rules of the Code. Please note that these guidelines differ 
from those for zoological nomenclature. 
Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or English. This 
does not affect the requirements for scientific names, which are still to be Latin. 
Also effective January 2012, the electronic PDF represents a published work according to the ICN for 
algae, fungi, and plants. Therefore the new names contained in the electronic publication of PLOS article 
are effectively published under that Code from the electronic edition alone, so there is no longer any need 
to provide printed copies. 
Solanum aspersum S.Knapp, sp. nov. [urn:lsid:ipni.org:names:77103633-1] Type: Colombia. Putumayo: vertiente oriental 
de la Cordillera, entre Sachamates y San Francisco de Sibundoy, 1600-1750 m, 30 Dec 1940, J. Cuatrecasas 11471 
(holotype, COL; isotypes, F [F-1335119], US [US-1799731]). 
Nomenclature, and hence the new names contained herein are available under that Code from the electronic edition of this 
article. This published work and the nomenclatural acts it contains have been registered in ZooBank, the online registration 
system for the ICZN. The ZooBank LSIDs (Life Science Identifiers) can be resolved and the associated information viewed 
through any standard web browser by appending the LSID to the prefix “http://zoobank.org/”. The LSID for this publication is: 
urn:lsid:zoobank.org:pub: XXXXXXX. The electronic edition of this work was published in a journal with an ISSN, and has 
been archived and is available from the following digital repositories: PubMed Central, LOCKSS [author to insert any 
additional repositories]. 
The electronic version of this article in Portable Document Format (PDF) in a work with an ISSN or ISBN will represent a 
published work according to the International Code of Nomenclature for algae, fungi, and plants, and hence the new names 
contained in the electronic publication of a PLOS article are effectively published under that Code from the electronic edition 
alone, so there is no longer any need to provide printed copies. 
In addition, new names contained in this work have been submitted to IPNI, from where they will be made available to the 
Global Names Index. The IPNI LSIDs can be resolved and the associated information viewed through any standard web 
browser by appending the LSID contained in this publication to the prefix http://ipni.org/. The online version of this work is 
archived and available from the following digital repositories: [INSERT NAMES OF DIGITAL REPOSITORIES WHERE 
ACCEPTED MANUSCRIPT WILL BE SUBMITTED (PubMed Central, LOCKSS etc)]. 
 
Additional information describing recent changes to the Code can be found here. 
For proper registration of the new taxon, we require two specific statements to be included in your 
manuscript. 
In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science Identifier 




You will need to contact either Mycobank or Index Fungorum to obtain the GUID (LSID). Please do this as 
early as possible to avoid delay of publication upon acceptance of your manuscript. It is your responsibility 
to provide us with this information so we can include it in the final published paper. Effective January 2013, 
all papers describing new fungal species must reference the identifier issued by a recognized repository in 
the protologue in order to be considered effectively published. 
In the Methods section, include a sub-section called “Nomenclature” using the following wording (this 
example is for taxon names submitted to MycoBank; please substitute appropriately if you have submitted 

























All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those of your co- 
authors, has its own repository, we recommend that you also deposit the published online article there and 





Qualitative research studies use non-quantitative methods to address a defined research question that may 
not be accessible by quantitative methods, such as people's interpretations, experiences, and perspectives. 
The analysis methods are explicit, systematic, and reproducible, but the results do not involve numerical 
values or use statistics. Examples of qualitative data sources include, but are not limited to, interviews, text 
documents, audio/video recordings, and free-form answers to questionnaires and surveys. 
Qualitative research studies should be reported in accordance to the Consolidated criteria for reporting 
qualitative research (COREQ) checklist. Further reporting guidelines can be found in the Equator 




Hymenogaster huthii. Stielow et al. 2010, sp. nov. [urn:lsid:indexfungorum.org:names:518624] 
The electronic version of this article in Portable Document Format (PDF) in a work with an ISSN or ISBN will represent a 
published work according to the International Code of Nomenclature for algae, fungi, and plants, and hence the new names 
contained in the electronic publication of a PLOS article are effectively published under that Code from the electronic edition 
alone, so there is no longer any need to provide printed copies. 
In addition, new names contained in this work have been submitted to MycoBank from where they will be made available to 
the Global Names Index. The unique MycoBank number can be resolved and the associated information viewed through any 
standard web browser by appending the MycoBank number contained in this publication to the prefix 
http://www.mycobank.org/MB/. The online version of this work is archived and available from the following digital repositories: 
[INSERT NAMES OF DIGITAL REPOSITORIES WHERE ACCEPTED MANUSCRIPT WILL BE SUBMITTED (PubMed 
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